[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQdQr83pOqqXMguG7XTLfqlCrBNrCHPyjtIJuGV9tnL0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"National University Hospital, Singapore",[4],435,false,88,21,128895,78,271,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Breast Cancer",31,{"name":18,"count":19},"Gastric Cancer",15,{"name":21,"count":22},"Stroke",12,{"name":24,"count":25},"Cancer",9,{"name":27,"count":28},"Non Small Cell Lung Cancer",8,{"name":30,"count":28},"Obesity",{"name":32,"count":33},"Tuberculosis",7,{"name":35,"count":36},"Lung Cancer",6,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06193993","Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients","2023-09-05","Abiraterone Acetate",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03813394","Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent\u002FMetastatic NPC","2024-07-31","pembrolizumab",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03519074","Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction","2024-09-01","TS-1 combined with cisplatin",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05687747","Single Centre Prospective Evaluation of 68Gallium-FAPI PET\u002FMRI in Hepatocellular Carcinoma","2025-08","Radiolabelled tracer, 68Gallium-FAPI-46 PET\u002FMRI",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT06690164","Study on the Effect of Atorvastatin Co-administered With Omeprazole on Statin Lactone","2025-12","Atorvastatin 40mg",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT07329582","Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine in Spinal Anaesthesia","2025-12-01","prilocaine",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05305131","Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer","2025-12-28","cisplatin and gemcitabine",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT07210528","Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study","2026-03","Emtricitabine",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05097911","Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.","2026-04","MTL-CEBPA",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT05038696","ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.","2026-05-01","CAR T-cell therapy",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,165,191,213,231,249,267,291,309,360,391,409,435,485,533,560,594,628,654,676,698,720,742,764,786,824,853,882,900,918,936,954,972,990,1015,1033,1057,1079,1097,1115,1133,1151,1176,1197,1221,1247,1274,1292,1310,1346,1364,1382,1400,1418,1436,1460,1478,1506,1524,1542,1560,1586,1609,1637,1671,1708,1732,1757,1779,1797,1815,1833,1856,1874,1892,1913,1937,1955,1981,2012,2038,2062,2088,2112,2130,2148,2166,2184,2209,2236,2261,2285,2310,2342,2366,2391,2417,2435,2463,2481,2499,2517,2542,2568,2586,2611,2629,2658,2676,2694,2712,2730,2755,2773,2791,2809,2872,2941,2977,3007,3029,3061,3090,3124,3150,3168,3186,3204,3228,3253,3277,3301,3326,3351,3378,3396,3418,3441,3459,3482,3505,3530,3555,3578,3604,3622,3640,3658,3681,3706,3724,3747,3771,3793,3817,3838,3861,3879,3903,3928,3946,3971,3989,4013,4040,4058,4081,4105,4131,4149,4167,4185,4212,4230,4248,4266,4289,4316,4334,4352,4375,4398,4421,4445,4469,4495,4517,4539,4565,4588,4612,4634,4655,4681,4699,4725,4748,4774,4796,4819,4837,4861,4886,4908,4932,4950,4968,4993,5011,5033,5058,5092,5120,5145,5180,5205,5229,5254,5272,5295,5318,5343,5366],{"intervention":97,"totalTrials":98,"cells":99},"Prednisolone",3,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":134,"PHASE4":136,"NA":163},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":133,"soonestReadout":112},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},"NCT06336395","Ma-Spore ALL 2020 Study","RECRUITING",[91],"2030-03","2020-03-04",500,[116],"B Lymphoblastic Leukemia",[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],"Dexamethasone","Vincristine","Methotrexate","L-Asparaginase","Pegylated asparaginase","Erwinase","Dasatinib","Imatinib","Cyclophosphamide","Cytarabine","Mercaptopurine","Thioguanine","Rituximab","Doxorubicin","Fludarabine",1,{"trials":135,"activeCount":102},[],{"trials":137,"activeCount":133,"soonestReadout":155},[138,150],{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":145,"interventions":147},"NCT02894645","Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study","UNKNOWN",[93],"2018-10","2008-10",[146],"Acute Lymphoblastic Leukemia (ALL)",[97,118,121,119,120,148,131,126,127,149,129,132,125],"Daunorubicin","6-Mercaptopurine",{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT06943482","Comparing Effectiveness of Steroids and Methotrexate in Treatment of Chronic Inflammatory Breast Disease","NOT_YET_RECRUITING",[93],"2028-02-01","2025-07-01",40,[159],"Idiopathic Granulomatous Mastitis",[97,120,161,162],"Folic Acid 5 MG","Omeprazole 20 mg",{"trials":164,"activeCount":102},[],{"intervention":120,"totalTrials":98,"cells":166},{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":177,"PHASE4":179,"NA":189},{"trials":168,"activeCount":102},[],{"trials":170,"activeCount":102},[],{"trials":172,"activeCount":133,"soonestReadout":112},[173],{"nctId":108,"briefTitle":109,"status":110,"phases":174,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":175,"interventions":176},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":178,"activeCount":102},[],{"trials":180,"activeCount":133,"soonestReadout":155},[181,185],{"nctId":139,"briefTitle":140,"status":141,"phases":182,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":183,"interventions":184},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"nctId":151,"briefTitle":152,"status":153,"phases":186,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":187,"interventions":188},[93],[159],[97,120,161,162],{"trials":190,"activeCount":102},[],{"intervention":62,"totalTrials":133,"cells":192},{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":201,"NA":211},{"trials":194,"activeCount":102},[],{"trials":196,"activeCount":102},[],{"trials":198,"activeCount":102},[],{"trials":200,"activeCount":102},[],{"trials":202,"activeCount":133,"soonestReadout":61},[203],{"nctId":59,"briefTitle":60,"status":110,"phases":204,"primaryCompletion":61,"completion":205,"start":206,"enrollment":11,"conditions":207,"interventions":209},[93],"2026-06","2025-06-12",[208],"Metabolite",[62,210],"Omeprazole 20mg",{"trials":212,"activeCount":102},[],{"intervention":210,"totalTrials":133,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":223,"NA":229},{"trials":216,"activeCount":102},[],{"trials":218,"activeCount":102},[],{"trials":220,"activeCount":102},[],{"trials":222,"activeCount":102},[],{"trials":224,"activeCount":133,"soonestReadout":61},[225],{"nctId":59,"briefTitle":60,"status":110,"phases":226,"primaryCompletion":61,"completion":205,"start":206,"enrollment":11,"conditions":227,"interventions":228},[93],[208],[62,210],{"trials":230,"activeCount":102},[],{"intervention":161,"totalTrials":133,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":247},{"trials":234,"activeCount":102},[],{"trials":236,"activeCount":102},[],{"trials":238,"activeCount":102},[],{"trials":240,"activeCount":102},[],{"trials":242,"activeCount":133,"soonestReadout":155},[243],{"nctId":151,"briefTitle":152,"status":153,"phases":244,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":245,"interventions":246},[93],[159],[97,120,161,162],{"trials":248,"activeCount":102},[],{"intervention":162,"totalTrials":133,"cells":250},{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":259,"NA":265},{"trials":252,"activeCount":102},[],{"trials":254,"activeCount":102},[],{"trials":256,"activeCount":102},[],{"trials":258,"activeCount":102},[],{"trials":260,"activeCount":133,"soonestReadout":155},[261],{"nctId":151,"briefTitle":152,"status":153,"phases":262,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":263,"interventions":264},[93],[159],[97,120,161,162],{"trials":266,"activeCount":102},[],{"intervention":67,"totalTrials":133,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":277,"NA":289},{"trials":270,"activeCount":102},[],{"trials":272,"activeCount":102},[],{"trials":274,"activeCount":102},[],{"trials":276,"activeCount":102},[],{"trials":278,"activeCount":133,"soonestReadout":66},[279],{"nctId":64,"briefTitle":65,"status":280,"phases":281,"primaryCompletion":66,"completion":205,"start":282,"enrollment":283,"conditions":284,"interventions":287},"ACTIVE_NOT_RECRUITING",[93],"2024-05-17",50,[285,286],"Knee Replacement, Total","Knee Replacement Surgery",[67,288],"Bupivacaine",{"trials":290,"activeCount":102},[],{"intervention":288,"totalTrials":133,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":301,"NA":307},{"trials":294,"activeCount":102},[],{"trials":296,"activeCount":102},[],{"trials":298,"activeCount":102},[],{"trials":300,"activeCount":102},[],{"trials":302,"activeCount":133,"soonestReadout":66},[303],{"nctId":64,"briefTitle":65,"status":280,"phases":304,"primaryCompletion":66,"completion":205,"start":282,"enrollment":283,"conditions":305,"interventions":306},[93],[285,286],[67,288],{"trials":308,"activeCount":102},[],{"intervention":310,"totalTrials":98,"cells":311},"Doxycycline",{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":343,"PHASE4":356,"NA":358},{"trials":313,"activeCount":102},[],{"trials":315,"activeCount":102},[],{"trials":317,"activeCount":133,"soonestReadout":322},[318,334],{"nctId":319,"briefTitle":320,"status":110,"phases":321,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":331},"NCT06446245","Adjunctive Doxycycline for Central Nervous System Tuberculosis",[91],"2027-11","2027-12","2025-08-21",200,[327,328,329,330],"Tuberculosis, Meningeal","Tuberculosis; Meningitis (Etiology)","Tuberculosis, Central Nervous System","Tuberculosis; Meningoencephalitis (Etiology)",[310,332,333],"Anti Tuberculosis Drug","Adjunctive corticosteroid",{"nctId":335,"briefTitle":336,"status":337,"phases":338,"primaryCompletion":339,"completion":339,"start":340,"enrollment":157,"conditions":341,"interventions":342},"NCT02774993","Doxycycline in Human Pulmonary Tuberculosis","COMPLETED",[91],"2017-06","2015-09",[32],[310],{"trials":344,"activeCount":133,"soonestReadout":349},[345],{"nctId":346,"briefTitle":347,"status":110,"phases":348,"primaryCompletion":349,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":355},"NCT05473520","Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis",[92],"2030-01-31","2023-05-24",150,[32,353,354],"Acute Coronary Syndrome","Pulmonary Hypertension (Diagnosis)",[310],{"trials":357,"activeCount":102},[],{"trials":359,"activeCount":102},[],{"intervention":361,"totalTrials":133,"cells":362},"Menopausal hormone therapy",{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":387,"NA":389},{"trials":364,"activeCount":102},[],{"trials":366,"activeCount":102},[],{"trials":368,"activeCount":102},[],{"trials":370,"activeCount":133,"soonestReadout":375},[371],{"nctId":372,"briefTitle":373,"status":110,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":385},"NCT06530459","The MUSE Study for Menopausal Arthralgia",[91,92],"2027-04","2028-04","2024-08-01",100,[380,381,382,383,384],"Arthralgia","Menopause","Perimenopausal Disorder","Joint Pain","Postmenopausal Disorder",[361,386],"Menopausal hormone therapy + exercise training",{"trials":388,"activeCount":102},[],{"trials":390,"activeCount":102},[],{"intervention":386,"totalTrials":133,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":405,"NA":407},{"trials":394,"activeCount":102},[],{"trials":396,"activeCount":102},[],{"trials":398,"activeCount":102},[],{"trials":400,"activeCount":133,"soonestReadout":375},[401],{"nctId":372,"briefTitle":373,"status":110,"phases":402,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":403,"interventions":404},[91,92],[380,381,382,383,384],[361,386],{"trials":406,"activeCount":102},[],{"trials":408,"activeCount":102},[],{"intervention":410,"totalTrials":133,"cells":411},"Systemic Therapy\u002FStandard of Care",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":431,"NA":433},{"trials":413,"activeCount":102},[],{"trials":415,"activeCount":102},[],{"trials":417,"activeCount":102},[],{"trials":419,"activeCount":133,"soonestReadout":424},[420],{"nctId":421,"briefTitle":422,"status":280,"phases":423,"primaryCompletion":424,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":430},"NCT07241715","Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)",[91,92],"2034-01","2026-02-21",300,[428,429],"Gastric Cancer Stage IV","Peritoneal Metastasis",[410],{"trials":432,"activeCount":102},[],{"trials":434,"activeCount":102},[],{"intervention":436,"totalTrials":98,"cells":437},"Pembrolizumab",{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":455,"PHASE3":479,"PHASE4":481,"NA":483},{"trials":439,"activeCount":102},[],{"trials":441,"activeCount":133,"soonestReadout":446},[442],{"nctId":443,"briefTitle":444,"status":110,"phases":445,"primaryCompletion":446,"completion":447,"start":448,"enrollment":449,"conditions":450,"interventions":452},"NCT06513624","ETC-159 In Combination With Pembrolizumab In Advanced MSS\u002FpMMR Ovarian Cancers",[90],"2026-12-31","2027-06-30","2024-12-09",16,[451],"With MSS\u002FpMMR Advanced, Platinum-resistant Ovarian Cancer",[453,436,454],"ETC-159","Denosumab \u002F Zoledronic Acid",{"trials":456,"activeCount":478,"soonestReadout":46},[457,467],{"nctId":44,"briefTitle":45,"status":280,"phases":458,"primaryCompletion":46,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":465},[90,91],"2025-06-01","2019-05-01",48,[463,464],"Locally Recurrent Cancer","Metastatic Nasopharyngeal Cancer",[47,466],"bevacizumab",{"nctId":468,"briefTitle":469,"status":110,"phases":470,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":476},"NCT06846268","Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer",[91],"2027-12-31","2025-04-14",20,[475],"Locally Advanced Colorectal Cancer",[477,436],"ADG126",2,{"trials":480,"activeCount":102},[],{"trials":482,"activeCount":102},[],{"trials":484,"activeCount":102},[],{"intervention":126,"totalTrials":486,"cells":487},4,{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":511,"PHASE4":525,"NA":531},{"trials":489,"activeCount":102},[],{"trials":491,"activeCount":102},[],{"trials":493,"activeCount":478,"soonestReadout":323},[494,498],{"nctId":108,"briefTitle":109,"status":110,"phases":495,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":496,"interventions":497},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"nctId":499,"briefTitle":500,"status":280,"phases":501,"primaryCompletion":323,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":508},"NCT05275777","A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer",[90,91],"2030-02","2022-05-19",66,[506,507],"HER2-negative Breast Cancer","Advanced Solid Tumor",[509,131,126,510],"ADG106","Paclitaxel",{"trials":512,"activeCount":102},[513],{"nctId":514,"briefTitle":515,"status":141,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":473,"conditions":519,"interventions":521},"NCT03759093","CURATE.AI Optimized Modulation for Multiple Myeloma",[91,92],"2025-09-10","2023-09-10",[520],"Multiple Myeloma",[522,126,118,523,522,126,523,118,524,524],"Bortezomib","Thalidomide","Lenalidomide",{"trials":526,"activeCount":102},[527],{"nctId":139,"briefTitle":140,"status":141,"phases":528,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":529,"interventions":530},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":532,"activeCount":102},[],{"intervention":466,"totalTrials":478,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":548,"PHASE3":554,"PHASE4":556,"NA":558},{"trials":536,"activeCount":102},[],{"trials":538,"activeCount":133,"soonestReadout":81},[539],{"nctId":79,"briefTitle":80,"status":280,"phases":540,"primaryCompletion":81,"completion":375,"start":541,"enrollment":542,"conditions":543,"interventions":545},[90],"2021-08-02",33,[544],"Advanced Hepatocellular Carcinoma",[82,546,547],"Atezolizumab","Bevacizumab",{"trials":549,"activeCount":133,"soonestReadout":46},[550],{"nctId":44,"briefTitle":45,"status":280,"phases":551,"primaryCompletion":46,"completion":459,"start":460,"enrollment":461,"conditions":552,"interventions":553},[90,91],[463,464],[47,466],{"trials":555,"activeCount":102},[],{"trials":557,"activeCount":102},[],{"trials":559,"activeCount":102},[],{"intervention":561,"totalTrials":478,"cells":562},"Lenvatinib + Letrozole",{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":564,"activeCount":102},[],{"trials":566,"activeCount":102},[],{"trials":568,"activeCount":478,"soonestReadout":583},[569,579],{"nctId":570,"briefTitle":571,"status":110,"phases":572,"primaryCompletion":573,"completion":573,"start":574,"enrollment":575,"conditions":576,"interventions":577},"NCT05181033","Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+\u002FHER2- Breast Cancer, Post Progression on Al + CDK4\u002F6 Inhibitor",[91],"2027-08","2021-12-27",120,[15],[561,578],"Fulvestrant",{"nctId":580,"briefTitle":581,"status":280,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":157,"conditions":586,"interventions":587},"NCT02562118","Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer",[90,91],"2027-01","2027-06","2015-10-02",[15],[561],{"trials":589,"activeCount":102},[],{"trials":591,"activeCount":102},[],{"trials":593,"activeCount":102},[],{"intervention":131,"totalTrials":486,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":610,"PHASE4":612,"NA":618},{"trials":597,"activeCount":102},[],{"trials":599,"activeCount":102},[],{"trials":601,"activeCount":478,"soonestReadout":323},[602,606],{"nctId":108,"briefTitle":109,"status":110,"phases":603,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":604,"interventions":605},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"nctId":499,"briefTitle":500,"status":280,"phases":607,"primaryCompletion":323,"completion":502,"start":503,"enrollment":504,"conditions":608,"interventions":609},[90,91],[506,507],[509,131,126,510],{"trials":611,"activeCount":102},[],{"trials":613,"activeCount":102},[614],{"nctId":139,"briefTitle":140,"status":141,"phases":615,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":616,"interventions":617},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":619,"activeCount":102},[620],{"nctId":621,"briefTitle":622,"status":141,"phases":623,"primaryCompletion":624,"start":625,"enrollment":114,"conditions":626,"interventions":627},"NCT02078388","Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients",[],"2015-10","2013-11",[15],[131],{"intervention":118,"totalTrials":98,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":640,"PHASE4":646,"NA":652},{"trials":631,"activeCount":102},[],{"trials":633,"activeCount":102},[],{"trials":635,"activeCount":133,"soonestReadout":112},[636],{"nctId":108,"briefTitle":109,"status":110,"phases":637,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":638,"interventions":639},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":641,"activeCount":102},[642],{"nctId":514,"briefTitle":515,"status":141,"phases":643,"primaryCompletion":517,"completion":517,"start":518,"enrollment":473,"conditions":644,"interventions":645},[91,92],[520],[522,126,118,523,522,126,523,118,524,524],{"trials":647,"activeCount":102},[648],{"nctId":139,"briefTitle":140,"status":141,"phases":649,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":650,"interventions":651},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":653,"activeCount":102},[],{"intervention":119,"totalTrials":478,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":666,"PHASE4":668,"NA":674},{"trials":657,"activeCount":102},[],{"trials":659,"activeCount":102},[],{"trials":661,"activeCount":133,"soonestReadout":112},[662],{"nctId":108,"briefTitle":109,"status":110,"phases":663,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":664,"interventions":665},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":667,"activeCount":102},[],{"trials":669,"activeCount":102},[670],{"nctId":139,"briefTitle":140,"status":141,"phases":671,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":672,"interventions":673},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":675,"activeCount":102},[],{"intervention":121,"totalTrials":478,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":688,"PHASE4":690,"NA":696},{"trials":679,"activeCount":102},[],{"trials":681,"activeCount":102},[],{"trials":683,"activeCount":133,"soonestReadout":112},[684],{"nctId":108,"briefTitle":109,"status":110,"phases":685,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":686,"interventions":687},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":689,"activeCount":102},[],{"trials":691,"activeCount":102},[692],{"nctId":139,"briefTitle":140,"status":141,"phases":693,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":694,"interventions":695},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":697,"activeCount":102},[],{"intervention":125,"totalTrials":478,"cells":699},{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":710,"PHASE4":712,"NA":718},{"trials":701,"activeCount":102},[],{"trials":703,"activeCount":102},[],{"trials":705,"activeCount":133,"soonestReadout":112},[706],{"nctId":108,"briefTitle":109,"status":110,"phases":707,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":708,"interventions":709},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":711,"activeCount":102},[],{"trials":713,"activeCount":102},[714],{"nctId":139,"briefTitle":140,"status":141,"phases":715,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":716,"interventions":717},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":719,"activeCount":102},[],{"intervention":127,"totalTrials":478,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":732,"PHASE4":734,"NA":740},{"trials":723,"activeCount":102},[],{"trials":725,"activeCount":102},[],{"trials":727,"activeCount":133,"soonestReadout":112},[728],{"nctId":108,"briefTitle":109,"status":110,"phases":729,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":730,"interventions":731},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":733,"activeCount":102},[],{"trials":735,"activeCount":102},[736],{"nctId":139,"briefTitle":140,"status":141,"phases":737,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":738,"interventions":739},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":741,"activeCount":102},[],{"intervention":129,"totalTrials":478,"cells":743},{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":754,"PHASE4":756,"NA":762},{"trials":745,"activeCount":102},[],{"trials":747,"activeCount":102},[],{"trials":749,"activeCount":133,"soonestReadout":112},[750],{"nctId":108,"briefTitle":109,"status":110,"phases":751,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":752,"interventions":753},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":755,"activeCount":102},[],{"trials":757,"activeCount":102},[758],{"nctId":139,"briefTitle":140,"status":141,"phases":759,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":760,"interventions":761},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":763,"activeCount":102},[],{"intervention":132,"totalTrials":478,"cells":765},{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":776,"PHASE4":778,"NA":784},{"trials":767,"activeCount":102},[],{"trials":769,"activeCount":102},[],{"trials":771,"activeCount":133,"soonestReadout":112},[772],{"nctId":108,"briefTitle":109,"status":110,"phases":773,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":774,"interventions":775},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":777,"activeCount":102},[],{"trials":779,"activeCount":102},[780],{"nctId":139,"briefTitle":140,"status":141,"phases":781,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":782,"interventions":783},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":785,"activeCount":102},[],{"intervention":510,"totalTrials":98,"cells":787},{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":812,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":789,"activeCount":102},[],{"trials":791,"activeCount":102},[792,802],{"nctId":793,"briefTitle":794,"status":141,"phases":795,"primaryCompletion":796,"completion":796,"start":797,"enrollment":798,"conditions":799,"interventions":801},"NCT05395910","Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis",[90],"2025-12-31","2023-08-04",36,[800],"Peritoneal Carcinomatosis",[510],{"nctId":803,"briefTitle":804,"status":141,"phases":805,"primaryCompletion":806,"completion":807,"start":340,"enrollment":808,"conditions":809,"interventions":811},"NCT02545010","Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer",[90],"2017-08","2018-08",24,[810],"Ovarian Cancer",[510],{"trials":813,"activeCount":133,"soonestReadout":323},[814],{"nctId":499,"briefTitle":500,"status":280,"phases":815,"primaryCompletion":323,"completion":502,"start":503,"enrollment":504,"conditions":816,"interventions":817},[90,91],[506,507],[509,131,126,510],{"trials":819,"activeCount":102},[],{"trials":821,"activeCount":102},[],{"trials":823,"activeCount":102},[],{"intervention":509,"totalTrials":478,"cells":825},{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":847,"PHASE4":849,"NA":851},{"trials":827,"activeCount":102},[],{"trials":829,"activeCount":102},[],{"trials":831,"activeCount":133,"soonestReadout":323},[832,836],{"nctId":499,"briefTitle":500,"status":280,"phases":833,"primaryCompletion":323,"completion":502,"start":503,"enrollment":504,"conditions":834,"interventions":835},[90,91],[506,507],[509,131,126,510],{"nctId":837,"briefTitle":838,"status":141,"phases":839,"primaryCompletion":840,"completion":840,"start":841,"enrollment":842,"conditions":843,"interventions":845},"NCT05236608","A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC",[90,91],"2024-05","2021-11-12",53,[844],"Metastatic Non Small Cell Lung Cancer",[846,509],"Nivolumab",{"trials":848,"activeCount":102},[],{"trials":850,"activeCount":102},[],{"trials":852,"activeCount":102},[],{"intervention":854,"totalTrials":133,"cells":855},"Azacitidine + docetaxel",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":876,"PHASE4":878,"NA":880},{"trials":857,"activeCount":102},[],{"trials":859,"activeCount":102},[],{"trials":861,"activeCount":133,"soonestReadout":866},[862],{"nctId":863,"briefTitle":864,"status":110,"phases":865,"primaryCompletion":866,"completion":867,"start":868,"enrollment":869,"conditions":870,"interventions":873},"NCT05381038","Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI",[90,91],"2026-10-04","2027-04-04","2023-02-13",10,[871,872,15],"Solid Tumor","Gastrointestinal Cancer",[854,874,875],"Azacitidine + paclitaxel","Azacitidine + irinotecan",{"trials":877,"activeCount":102},[],{"trials":879,"activeCount":102},[],{"trials":881,"activeCount":102},[],{"intervention":874,"totalTrials":133,"cells":883},{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":885,"activeCount":102},[],{"trials":887,"activeCount":102},[],{"trials":889,"activeCount":133,"soonestReadout":866},[890],{"nctId":863,"briefTitle":864,"status":110,"phases":891,"primaryCompletion":866,"completion":867,"start":868,"enrollment":869,"conditions":892,"interventions":893},[90,91],[871,872,15],[854,874,875],{"trials":895,"activeCount":102},[],{"trials":897,"activeCount":102},[],{"trials":899,"activeCount":102},[],{"intervention":875,"totalTrials":133,"cells":901},{"EARLY_PHASE1":902,"PHASE1":904,"PHASE2":906,"PHASE3":912,"PHASE4":914,"NA":916},{"trials":903,"activeCount":102},[],{"trials":905,"activeCount":102},[],{"trials":907,"activeCount":133,"soonestReadout":866},[908],{"nctId":863,"briefTitle":864,"status":110,"phases":909,"primaryCompletion":866,"completion":867,"start":868,"enrollment":869,"conditions":910,"interventions":911},[90,91],[871,872,15],[854,874,875],{"trials":913,"activeCount":102},[],{"trials":915,"activeCount":102},[],{"trials":917,"activeCount":102},[],{"intervention":122,"totalTrials":133,"cells":919},{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":930,"PHASE4":932,"NA":934},{"trials":921,"activeCount":102},[],{"trials":923,"activeCount":102},[],{"trials":925,"activeCount":133,"soonestReadout":112},[926],{"nctId":108,"briefTitle":109,"status":110,"phases":927,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":928,"interventions":929},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":931,"activeCount":102},[],{"trials":933,"activeCount":102},[],{"trials":935,"activeCount":102},[],{"intervention":123,"totalTrials":133,"cells":937},{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":939,"activeCount":102},[],{"trials":941,"activeCount":102},[],{"trials":943,"activeCount":133,"soonestReadout":112},[944],{"nctId":108,"briefTitle":109,"status":110,"phases":945,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":946,"interventions":947},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":949,"activeCount":102},[],{"trials":951,"activeCount":102},[],{"trials":953,"activeCount":102},[],{"intervention":124,"totalTrials":133,"cells":955},{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":957,"activeCount":102},[],{"trials":959,"activeCount":102},[],{"trials":961,"activeCount":133,"soonestReadout":112},[962],{"nctId":108,"briefTitle":109,"status":110,"phases":963,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":964,"interventions":965},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":967,"activeCount":102},[],{"trials":969,"activeCount":102},[],{"trials":971,"activeCount":102},[],{"intervention":128,"totalTrials":133,"cells":973},{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":975,"activeCount":102},[],{"trials":977,"activeCount":102},[],{"trials":979,"activeCount":133,"soonestReadout":112},[980],{"nctId":108,"briefTitle":109,"status":110,"phases":981,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":982,"interventions":983},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":985,"activeCount":102},[],{"trials":987,"activeCount":102},[],{"trials":989,"activeCount":102},[],{"intervention":991,"totalTrials":133,"cells":992},"Chimeric receptor T-cells + Trastuzumab",{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":1009,"PHASE4":1011,"NA":1013},{"trials":994,"activeCount":102},[],{"trials":996,"activeCount":102},[],{"trials":998,"activeCount":133,"soonestReadout":446},[999],{"nctId":1000,"briefTitle":1001,"status":153,"phases":1002,"primaryCompletion":446,"completion":471,"start":1003,"enrollment":798,"conditions":1004,"interventions":1007},"NCT06027983","Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors",[90,91],"2026-11-01",[1005,1006],"HER2+ Advanced Breast Cancer","Other Solid Tumors",[991,1008],"Fludarabine and Cyclophosphosphamide",{"trials":1010,"activeCount":102},[],{"trials":1012,"activeCount":102},[],{"trials":1014,"activeCount":102},[],{"intervention":1008,"totalTrials":133,"cells":1016},{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1027,"PHASE4":1029,"NA":1031},{"trials":1018,"activeCount":102},[],{"trials":1020,"activeCount":102},[],{"trials":1022,"activeCount":133,"soonestReadout":446},[1023],{"nctId":1000,"briefTitle":1001,"status":153,"phases":1024,"primaryCompletion":446,"completion":471,"start":1003,"enrollment":798,"conditions":1025,"interventions":1026},[90,91],[1005,1006],[991,1008],{"trials":1028,"activeCount":102},[],{"trials":1030,"activeCount":102},[],{"trials":1032,"activeCount":102},[],{"intervention":1034,"totalTrials":133,"cells":1035},"Pembrolizumab & ADG106",{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1051,"PHASE4":1053,"NA":1055},{"trials":1037,"activeCount":102},[],{"trials":1039,"activeCount":102},[],{"trials":1041,"activeCount":133,"soonestReadout":446},[1042],{"nctId":1043,"briefTitle":1044,"status":110,"phases":1045,"primaryCompletion":446,"completion":446,"start":1046,"enrollment":1047,"conditions":1048,"interventions":1050},"NCT05491083","Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer",[90,91],"2023-06-12",51,[507,1049],"Triple Negative Breast Cancer",[1034,1034],{"trials":1052,"activeCount":102},[],{"trials":1054,"activeCount":102},[],{"trials":1056,"activeCount":102},[],{"intervention":72,"totalTrials":133,"cells":1058},{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1073,"PHASE4":1075,"NA":1077},{"trials":1060,"activeCount":102},[],{"trials":1062,"activeCount":102},[],{"trials":1064,"activeCount":133,"soonestReadout":71},[1065],{"nctId":69,"briefTitle":70,"status":110,"phases":1066,"primaryCompletion":71,"completion":1067,"start":1068,"enrollment":283,"conditions":1069,"interventions":1071},[91],"2026-12-28","2022-03-28",[1070],"Nasopharyngeal Cancer",[72,1072],"induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.",{"trials":1074,"activeCount":102},[],{"trials":1076,"activeCount":102},[],{"trials":1078,"activeCount":102},[],{"intervention":1072,"totalTrials":133,"cells":1080},{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1091,"PHASE4":1093,"NA":1095},{"trials":1082,"activeCount":102},[],{"trials":1084,"activeCount":102},[],{"trials":1086,"activeCount":133,"soonestReadout":71},[1087],{"nctId":69,"briefTitle":70,"status":110,"phases":1088,"primaryCompletion":71,"completion":1067,"start":1068,"enrollment":283,"conditions":1089,"interventions":1090},[91],[1070],[72,1072],{"trials":1092,"activeCount":102},[],{"trials":1094,"activeCount":102},[],{"trials":1096,"activeCount":102},[],{"intervention":578,"totalTrials":133,"cells":1098},{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1109,"PHASE4":1111,"NA":1113},{"trials":1100,"activeCount":102},[],{"trials":1102,"activeCount":102},[],{"trials":1104,"activeCount":133,"soonestReadout":573},[1105],{"nctId":570,"briefTitle":571,"status":110,"phases":1106,"primaryCompletion":573,"completion":573,"start":574,"enrollment":575,"conditions":1107,"interventions":1108},[91],[15],[561,578],{"trials":1110,"activeCount":102},[],{"trials":1112,"activeCount":102},[],{"trials":1114,"activeCount":102},[],{"intervention":332,"totalTrials":133,"cells":1116},{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1127,"PHASE4":1129,"NA":1131},{"trials":1118,"activeCount":102},[],{"trials":1120,"activeCount":102},[],{"trials":1122,"activeCount":133,"soonestReadout":322},[1123],{"nctId":319,"briefTitle":320,"status":110,"phases":1124,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":1125,"interventions":1126},[91],[327,328,329,330],[310,332,333],{"trials":1128,"activeCount":102},[],{"trials":1130,"activeCount":102},[],{"trials":1132,"activeCount":102},[],{"intervention":333,"totalTrials":133,"cells":1134},{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1139,"PHASE3":1145,"PHASE4":1147,"NA":1149},{"trials":1136,"activeCount":102},[],{"trials":1138,"activeCount":102},[],{"trials":1140,"activeCount":133,"soonestReadout":322},[1141],{"nctId":319,"briefTitle":320,"status":110,"phases":1142,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":1143,"interventions":1144},[91],[327,328,329,330],[310,332,333],{"trials":1146,"activeCount":102},[],{"trials":1148,"activeCount":102},[],{"trials":1150,"activeCount":102},[],{"intervention":1152,"totalTrials":133,"cells":1153},"Ivonescimab 20 mg\u002Fkg",{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1170,"PHASE4":1172,"NA":1174},{"trials":1155,"activeCount":102},[],{"trials":1157,"activeCount":102},[],{"trials":1159,"activeCount":133,"soonestReadout":1164},[1160],{"nctId":1161,"briefTitle":1162,"status":153,"phases":1163,"primaryCompletion":1164,"completion":1164,"start":1165,"enrollment":1166,"conditions":1167,"interventions":1169},"NCT07565389","Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma",[91],"2031-05","2026-05",42,[1168],"Nasopharyngeal Carcinoma (NPC)",[1152],{"trials":1171,"activeCount":102},[],{"trials":1173,"activeCount":102},[],{"trials":1175,"activeCount":102},[],{"intervention":52,"totalTrials":133,"cells":1177},{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1182,"PHASE3":1191,"PHASE4":1193,"NA":1195},{"trials":1179,"activeCount":102},[],{"trials":1181,"activeCount":102},[],{"trials":1183,"activeCount":133,"soonestReadout":51},[1184],{"nctId":49,"briefTitle":50,"status":280,"phases":1185,"primaryCompletion":51,"completion":1186,"start":1187,"enrollment":461,"conditions":1188,"interventions":1190},[91],"2025-12-20","2016-07-22",[24,1189],"Liver Dysfunction",[52],{"trials":1192,"activeCount":102},[],{"trials":1194,"activeCount":102},[],{"trials":1196,"activeCount":102},[],{"intervention":1198,"totalTrials":133,"cells":1199},"Pacritinib",{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1215,"PHASE4":1217,"NA":1219},{"trials":1201,"activeCount":102},[],{"trials":1203,"activeCount":102},[],{"trials":1205,"activeCount":133,"soonestReadout":1210},[1206],{"nctId":1207,"briefTitle":1208,"status":280,"phases":1209,"primaryCompletion":1210,"completion":1210,"start":1211,"enrollment":1212,"conditions":1213,"interventions":1214},"NCT04520269","A Single Arm, Phase Ib\u002FII Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)",[90,91],"2026-07","2020-07-13",74,[15],[1198],{"trials":1216,"activeCount":102},[],{"trials":1218,"activeCount":102},[],{"trials":1220,"activeCount":102},[],{"intervention":1222,"totalTrials":133,"cells":1223},"Afatinib 40 MG",{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1241,"PHASE4":1243,"NA":1245},{"trials":1225,"activeCount":102},[],{"trials":1227,"activeCount":102},[],{"trials":1229,"activeCount":133,"soonestReadout":1234},[1230],{"nctId":1231,"briefTitle":1232,"status":110,"phases":1233,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":1238,"interventions":1240},"NCT06062823","Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations",[91],"2026-10","2026-12","2024-03-25",35,[1239],"NSCLC",[1222],{"trials":1242,"activeCount":102},[],{"trials":1244,"activeCount":102},[],{"trials":1246,"activeCount":102},[],{"intervention":1248,"totalTrials":133,"cells":1249},"Talazoparib",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1268,"PHASE4":1270,"NA":1272},{"trials":1251,"activeCount":102},[],{"trials":1253,"activeCount":102},[],{"trials":1255,"activeCount":133,"soonestReadout":322},[1256],{"nctId":1257,"briefTitle":1258,"status":110,"phases":1259,"primaryCompletion":322,"completion":322,"start":1260,"enrollment":1261,"conditions":1262,"interventions":1266},"NCT05035745","Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced\u002FMetastatic Triple Negative Breast Cancer (START)",[90,91],"2021-03-01",63,[1263,1264,1265],"Advanced Refractory Solid Tumors","Advanced Triple Negative Breast Cancers","Metastatic Triple Negative Breast Cancers",[1248,1267],"Selinexor",{"trials":1269,"activeCount":102},[],{"trials":1271,"activeCount":102},[],{"trials":1273,"activeCount":102},[],{"intervention":1267,"totalTrials":133,"cells":1275},{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1286,"PHASE4":1288,"NA":1290},{"trials":1277,"activeCount":102},[],{"trials":1279,"activeCount":102},[],{"trials":1281,"activeCount":133,"soonestReadout":322},[1282],{"nctId":1257,"briefTitle":1258,"status":110,"phases":1283,"primaryCompletion":322,"completion":322,"start":1260,"enrollment":1261,"conditions":1284,"interventions":1285},[90,91],[1263,1264,1265],[1248,1267],{"trials":1287,"activeCount":102},[],{"trials":1289,"activeCount":102},[],{"trials":1291,"activeCount":102},[],{"intervention":477,"totalTrials":133,"cells":1293},{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1295,"activeCount":102},[],{"trials":1297,"activeCount":102},[],{"trials":1299,"activeCount":133,"soonestReadout":471},[1300],{"nctId":468,"briefTitle":469,"status":110,"phases":1301,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":1302,"interventions":1303},[91],[475],[477,436],{"trials":1305,"activeCount":102},[],{"trials":1307,"activeCount":102},[],{"trials":1309,"activeCount":102},[],{"intervention":1311,"totalTrials":133,"cells":1312},"Extended Dosing Interval - A",{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1340,"PHASE4":1342,"NA":1344},{"trials":1314,"activeCount":102},[],{"trials":1316,"activeCount":102},[],{"trials":1318,"activeCount":133,"soonestReadout":1323},[1319],{"nctId":1320,"briefTitle":1321,"status":110,"phases":1322,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1326,"conditions":1327,"interventions":1334},"NCT06422403","A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers",[91],"2029-03-30","2029-12-31","2024-11-25",360,[1328,1329,1330,1331,1332,1333],"Carcinoma, Hepatocellular","Gastric Adenocarcinoma","GastroEsophageal Cancer","Oesophageal Cancer","Non-small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma",[1311,1335,1336,1337,1338,1339],"Extended Dosing Interval - B","Extended Dosing Interval - C","Standard of Care - A","Standard of Care - B","Standard of Care - C",{"trials":1341,"activeCount":102},[],{"trials":1343,"activeCount":102},[],{"trials":1345,"activeCount":102},[],{"intervention":1335,"totalTrials":133,"cells":1347},{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1349,"activeCount":102},[],{"trials":1351,"activeCount":102},[],{"trials":1353,"activeCount":133,"soonestReadout":1323},[1354],{"nctId":1320,"briefTitle":1321,"status":110,"phases":1355,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1326,"conditions":1356,"interventions":1357},[91],[1328,1329,1330,1331,1332,1333],[1311,1335,1336,1337,1338,1339],{"trials":1359,"activeCount":102},[],{"trials":1361,"activeCount":102},[],{"trials":1363,"activeCount":102},[],{"intervention":1336,"totalTrials":133,"cells":1365},{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1376,"PHASE4":1378,"NA":1380},{"trials":1367,"activeCount":102},[],{"trials":1369,"activeCount":102},[],{"trials":1371,"activeCount":133,"soonestReadout":1323},[1372],{"nctId":1320,"briefTitle":1321,"status":110,"phases":1373,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1326,"conditions":1374,"interventions":1375},[91],[1328,1329,1330,1331,1332,1333],[1311,1335,1336,1337,1338,1339],{"trials":1377,"activeCount":102},[],{"trials":1379,"activeCount":102},[],{"trials":1381,"activeCount":102},[],{"intervention":1337,"totalTrials":133,"cells":1383},{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1394,"PHASE4":1396,"NA":1398},{"trials":1385,"activeCount":102},[],{"trials":1387,"activeCount":102},[],{"trials":1389,"activeCount":133,"soonestReadout":1323},[1390],{"nctId":1320,"briefTitle":1321,"status":110,"phases":1391,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1326,"conditions":1392,"interventions":1393},[91],[1328,1329,1330,1331,1332,1333],[1311,1335,1336,1337,1338,1339],{"trials":1395,"activeCount":102},[],{"trials":1397,"activeCount":102},[],{"trials":1399,"activeCount":102},[],{"intervention":1338,"totalTrials":133,"cells":1401},{"EARLY_PHASE1":1402,"PHASE1":1404,"PHASE2":1406,"PHASE3":1412,"PHASE4":1414,"NA":1416},{"trials":1403,"activeCount":102},[],{"trials":1405,"activeCount":102},[],{"trials":1407,"activeCount":133,"soonestReadout":1323},[1408],{"nctId":1320,"briefTitle":1321,"status":110,"phases":1409,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1326,"conditions":1410,"interventions":1411},[91],[1328,1329,1330,1331,1332,1333],[1311,1335,1336,1337,1338,1339],{"trials":1413,"activeCount":102},[],{"trials":1415,"activeCount":102},[],{"trials":1417,"activeCount":102},[],{"intervention":1339,"totalTrials":133,"cells":1419},{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1430,"PHASE4":1432,"NA":1434},{"trials":1421,"activeCount":102},[],{"trials":1423,"activeCount":102},[],{"trials":1425,"activeCount":133,"soonestReadout":1323},[1426],{"nctId":1320,"briefTitle":1321,"status":110,"phases":1427,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1326,"conditions":1428,"interventions":1429},[91],[1328,1329,1330,1331,1332,1333],[1311,1335,1336,1337,1338,1339],{"trials":1431,"activeCount":102},[],{"trials":1433,"activeCount":102},[],{"trials":1435,"activeCount":102},[],{"intervention":1437,"totalTrials":133,"cells":1438},"Cohort A",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1454,"PHASE4":1456,"NA":1458},{"trials":1440,"activeCount":102},[],{"trials":1442,"activeCount":102},[],{"trials":1444,"activeCount":133,"soonestReadout":205},[1445],{"nctId":1446,"briefTitle":1447,"status":280,"phases":1448,"primaryCompletion":205,"completion":205,"start":1449,"enrollment":1450,"conditions":1451,"interventions":1452},"NCT04280536","Phase II Study of FTD\u002FTPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)",[90,91],"2019-08-14",86,[15],[1437,1453],"Cohort B",{"trials":1455,"activeCount":102},[],{"trials":1457,"activeCount":102},[],{"trials":1459,"activeCount":102},[],{"intervention":1453,"totalTrials":133,"cells":1461},{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1472,"PHASE4":1474,"NA":1476},{"trials":1463,"activeCount":102},[],{"trials":1465,"activeCount":102},[],{"trials":1467,"activeCount":133,"soonestReadout":205},[1468],{"nctId":1446,"briefTitle":1447,"status":280,"phases":1469,"primaryCompletion":205,"completion":205,"start":1449,"enrollment":1450,"conditions":1470,"interventions":1471},[90,91],[15],[1437,1453],{"trials":1473,"activeCount":102},[],{"trials":1475,"activeCount":102},[],{"trials":1477,"activeCount":102},[],{"intervention":1479,"totalTrials":133,"cells":1480},"Dupilumab",{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1485,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1482,"activeCount":102},[],{"trials":1484,"activeCount":102},[],{"trials":1486,"activeCount":133,"soonestReadout":1491},[1487],{"nctId":1488,"briefTitle":1489,"status":110,"phases":1490,"primaryCompletion":1491,"completion":1491,"start":1492,"enrollment":504,"conditions":1493,"interventions":1496},"NCT07091175","Dupilumab Therapy in Nephrotic Syndrome in Children",[91],"2028-02-28","2025-11-27",[1494,1495],"Nephrotic Syndrome in Children","Nephrotic Syndrome Steroid-Dependent",[1479,1497,1498,1499],"Co-intervention of Prednisolone wean during randomised controlled phase","Dupilumab open label extension phase","Co-intervention of Prednisolone wean during open label extension phase",{"trials":1501,"activeCount":102},[],{"trials":1503,"activeCount":102},[],{"trials":1505,"activeCount":102},[],{"intervention":1497,"totalTrials":133,"cells":1507},{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1518,"PHASE4":1520,"NA":1522},{"trials":1509,"activeCount":102},[],{"trials":1511,"activeCount":102},[],{"trials":1513,"activeCount":133,"soonestReadout":1491},[1514],{"nctId":1488,"briefTitle":1489,"status":110,"phases":1515,"primaryCompletion":1491,"completion":1491,"start":1492,"enrollment":504,"conditions":1516,"interventions":1517},[91],[1494,1495],[1479,1497,1498,1499],{"trials":1519,"activeCount":102},[],{"trials":1521,"activeCount":102},[],{"trials":1523,"activeCount":102},[],{"intervention":1498,"totalTrials":133,"cells":1525},{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1527,"activeCount":102},[],{"trials":1529,"activeCount":102},[],{"trials":1531,"activeCount":133,"soonestReadout":1491},[1532],{"nctId":1488,"briefTitle":1489,"status":110,"phases":1533,"primaryCompletion":1491,"completion":1491,"start":1492,"enrollment":504,"conditions":1534,"interventions":1535},[91],[1494,1495],[1479,1497,1498,1499],{"trials":1537,"activeCount":102},[],{"trials":1539,"activeCount":102},[],{"trials":1541,"activeCount":102},[],{"intervention":1499,"totalTrials":133,"cells":1543},{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1545,"activeCount":102},[],{"trials":1547,"activeCount":102},[],{"trials":1549,"activeCount":133,"soonestReadout":1491},[1550],{"nctId":1488,"briefTitle":1489,"status":110,"phases":1551,"primaryCompletion":1491,"completion":1491,"start":1492,"enrollment":504,"conditions":1552,"interventions":1553},[91],[1494,1495],[1479,1497,1498,1499],{"trials":1555,"activeCount":102},[],{"trials":1557,"activeCount":102},[],{"trials":1559,"activeCount":102},[],{"intervention":1561,"totalTrials":133,"cells":1562},"Sacituzumab govitecan",{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1564,"activeCount":102},[],{"trials":1566,"activeCount":102},[],{"trials":1568,"activeCount":133,"soonestReadout":1573},[1569],{"nctId":1570,"briefTitle":1571,"status":110,"phases":1572,"primaryCompletion":1573,"completion":1573,"start":1574,"enrollment":1575,"conditions":1576,"interventions":1579},"NCT06923826","Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)",[91],"2030-04","2025-04-15",32,[1577,1578],"Salivary Gland Cancer","Thyroid Cancer",[1561],{"trials":1581,"activeCount":102},[],{"trials":1583,"activeCount":102},[],{"trials":1585,"activeCount":102},[],{"intervention":1587,"totalTrials":133,"cells":1588},"Pyrvinium",{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1590,"activeCount":102},[],{"trials":1592,"activeCount":102},[],{"trials":1594,"activeCount":133,"soonestReadout":1599},[1595],{"nctId":1596,"briefTitle":1597,"status":153,"phases":1598,"primaryCompletion":1599,"completion":1599,"start":56,"enrollment":283,"conditions":1600,"interventions":1602},"NCT06782048","Use of Pyrvinium to Reverse Stomach Precancerous Conditions",[91],"2029-12",[1601],"STOMACH NEOPLASM",[1587],{"trials":1604,"activeCount":102},[],{"trials":1606,"activeCount":102},[],{"trials":1608,"activeCount":102},[],{"intervention":130,"totalTrials":478,"cells":1610},{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1615,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1612,"activeCount":102},[],{"trials":1614,"activeCount":102},[],{"trials":1616,"activeCount":133,"soonestReadout":112},[1617],{"nctId":108,"briefTitle":109,"status":110,"phases":1618,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":1619,"interventions":1620},[91],[116],[97,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],{"trials":1622,"activeCount":102},[],{"trials":1624,"activeCount":102},[],{"trials":1626,"activeCount":102},[1627],{"nctId":1628,"briefTitle":1629,"status":337,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1636},"NCT01482754","Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma",[94],"2013-04","2012-05",30,[1635],"Non Hodgkin Lymphoma",[130],{"intervention":87,"totalTrials":478,"cells":1638},{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1663,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1640,"activeCount":102},[],{"trials":1642,"activeCount":478,"soonestReadout":86},[1643,1655],{"nctId":84,"briefTitle":85,"status":110,"phases":1644,"primaryCompletion":86,"completion":1645,"start":1646,"enrollment":157,"conditions":1647,"interventions":1654},[90],"2026-08-01","2021-04-28",[1648,1649,1650,1651,1652,1653],"Lymphoblastic Leukemia, Acute, Childhood","Lymphoblastic Leukemia","Lymphoblastic Leukemia, Acute Adult","Lymphoblastic Leukemia in Children","CAR","CAR T-Cell-Related Encephalopathy Syndrome",[87],{"nctId":1656,"briefTitle":1657,"status":110,"phases":1658,"primaryCompletion":1003,"completion":1003,"start":1659,"enrollment":473,"conditions":1660,"interventions":1662},"NCT05043571","CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed\u002F Refractory T-Lineage Acute Lymphoblastic Leukaemia",[90],"2021-09-08",[1648,1649,1650,1651,1652,1653,1661],"Refractory Leukemia",[87],{"trials":1664,"activeCount":102},[],{"trials":1666,"activeCount":102},[],{"trials":1668,"activeCount":102},[],{"trials":1670,"activeCount":102},[],{"intervention":1672,"totalTrials":478,"cells":1673},"Ciprofloxacin",{"EARLY_PHASE1":1674,"PHASE1":1676,"PHASE2":1687,"PHASE3":1689,"PHASE4":1691,"NA":1706},{"trials":1675,"activeCount":102},[],{"trials":1677,"activeCount":133,"soonestReadout":1682},[1678],{"nctId":1679,"briefTitle":1680,"status":280,"phases":1681,"primaryCompletion":1682,"completion":1682,"start":1683,"enrollment":869,"conditions":1684,"interventions":1686},"NCT04523987","A Pilot Study of Ciprofloxacin Plus Gemcitabine and Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.",[90],"2027-02","2019-02-22",[1685],"Metastatic Pancreatic Ductal Adenocarcinoma",[1672],{"trials":1688,"activeCount":102},[],{"trials":1690,"activeCount":102},[],{"trials":1692,"activeCount":102},[1693],{"nctId":1694,"briefTitle":1695,"status":337,"phases":1696,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1699,"conditions":1700,"interventions":1702},"NCT01723150","Antibiotics for Klebsiella Liver Abscess Study",[93],"2018-01-16","2013-11-05",152,[1701],"Liver Abscess, Pyogenic",[1672,1703,1704,1705],"Ceftriaxone","Trimethoprim\u002Fsulfamethoxazole","Ertapenem",{"trials":1707,"activeCount":102},[],{"intervention":42,"totalTrials":133,"cells":1709},{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1724,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1711,"activeCount":102},[],{"trials":1713,"activeCount":133,"soonestReadout":41},[1714],{"nctId":39,"briefTitle":40,"status":280,"phases":1715,"primaryCompletion":41,"completion":1716,"start":1717,"enrollment":869,"conditions":1718,"interventions":1723},[90],"2026-09","2021-11-30",[1719,1720,1721,1722],"Prostate Cancer","Metastatic Cancer","Hormone Sensitive Prostate Cancer","Castration-resistant Prostate Cancer",[42],{"trials":1725,"activeCount":102},[],{"trials":1727,"activeCount":102},[],{"trials":1729,"activeCount":102},[],{"trials":1731,"activeCount":102},[],{"intervention":1733,"totalTrials":133,"cells":1734},"PRL3-ZUMAB",{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1749,"PHASE3":1751,"PHASE4":1753,"NA":1755},{"trials":1736,"activeCount":102},[],{"trials":1738,"activeCount":133,"soonestReadout":1743},[1739],{"nctId":1740,"briefTitle":1741,"status":280,"phases":1742,"primaryCompletion":1743,"completion":1743,"start":1744,"enrollment":1745,"conditions":1746,"interventions":1748},"NCT03191682","A First-in-Human Study of PRL3-ZUMAB",[90],"2027-02-20","2017-02-20",38,[1747],"Advanced Solid Tumors",[1733],{"trials":1750,"activeCount":102},[],{"trials":1752,"activeCount":102},[],{"trials":1754,"activeCount":102},[],{"trials":1756,"activeCount":102},[],{"intervention":77,"totalTrials":133,"cells":1758},{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1771,"PHASE3":1773,"PHASE4":1775,"NA":1777},{"trials":1760,"activeCount":102},[],{"trials":1762,"activeCount":133,"soonestReadout":76},[1763],{"nctId":74,"briefTitle":75,"status":110,"phases":1764,"primaryCompletion":76,"completion":81,"start":1765,"enrollment":461,"conditions":1766,"interventions":1769},[90],"2025-06-30",[1767,1768],"Mild Cognitive Impairment (MCI)","Alzheimer Dementia (AD)",[77,1770],"Descovy®",{"trials":1772,"activeCount":102},[],{"trials":1774,"activeCount":102},[],{"trials":1776,"activeCount":102},[],{"trials":1778,"activeCount":102},[],{"intervention":1770,"totalTrials":133,"cells":1780},{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1789,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1782,"activeCount":102},[],{"trials":1784,"activeCount":133,"soonestReadout":76},[1785],{"nctId":74,"briefTitle":75,"status":110,"phases":1786,"primaryCompletion":76,"completion":81,"start":1765,"enrollment":461,"conditions":1787,"interventions":1788},[90],[1767,1768],[77,1770],{"trials":1790,"activeCount":102},[],{"trials":1792,"activeCount":102},[],{"trials":1794,"activeCount":102},[],{"trials":1796,"activeCount":102},[],{"intervention":453,"totalTrials":133,"cells":1798},{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1807,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1800,"activeCount":102},[],{"trials":1802,"activeCount":133,"soonestReadout":446},[1803],{"nctId":443,"briefTitle":444,"status":110,"phases":1804,"primaryCompletion":446,"completion":447,"start":448,"enrollment":449,"conditions":1805,"interventions":1806},[90],[451],[453,436,454],{"trials":1808,"activeCount":102},[],{"trials":1810,"activeCount":102},[],{"trials":1812,"activeCount":102},[],{"trials":1814,"activeCount":102},[],{"intervention":454,"totalTrials":133,"cells":1816},{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1825,"PHASE3":1827,"PHASE4":1829,"NA":1831},{"trials":1818,"activeCount":102},[],{"trials":1820,"activeCount":133,"soonestReadout":446},[1821],{"nctId":443,"briefTitle":444,"status":110,"phases":1822,"primaryCompletion":446,"completion":447,"start":448,"enrollment":449,"conditions":1823,"interventions":1824},[90],[451],[453,436,454],{"trials":1826,"activeCount":102},[],{"trials":1828,"activeCount":102},[],{"trials":1830,"activeCount":102},[],{"trials":1832,"activeCount":102},[],{"intervention":1834,"totalTrials":133,"cells":1835},"AZD5363+Olaparib+Durvalumab",{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1848,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1837,"activeCount":102},[],{"trials":1839,"activeCount":133,"soonestReadout":446},[1840],{"nctId":1841,"briefTitle":1842,"status":110,"phases":1843,"primaryCompletion":446,"completion":446,"start":1844,"enrollment":157,"conditions":1845,"interventions":1847},"NCT03772561","Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies",[90],"2018-12-03",[1846],"Solid Tumor, Adult",[1834],{"trials":1849,"activeCount":102},[],{"trials":1851,"activeCount":102},[],{"trials":1853,"activeCount":102},[],{"trials":1855,"activeCount":102},[],{"intervention":82,"totalTrials":133,"cells":1857},{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1866,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1859,"activeCount":102},[],{"trials":1861,"activeCount":133,"soonestReadout":81},[1862],{"nctId":79,"briefTitle":80,"status":280,"phases":1863,"primaryCompletion":81,"completion":375,"start":541,"enrollment":542,"conditions":1864,"interventions":1865},[90],[544],[82,546,547],{"trials":1867,"activeCount":102},[],{"trials":1869,"activeCount":102},[],{"trials":1871,"activeCount":102},[],{"trials":1873,"activeCount":102},[],{"intervention":546,"totalTrials":133,"cells":1875},{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1884,"PHASE3":1886,"PHASE4":1888,"NA":1890},{"trials":1877,"activeCount":102},[],{"trials":1879,"activeCount":133,"soonestReadout":81},[1880],{"nctId":79,"briefTitle":80,"status":280,"phases":1881,"primaryCompletion":81,"completion":375,"start":541,"enrollment":542,"conditions":1882,"interventions":1883},[90],[544],[82,546,547],{"trials":1885,"activeCount":102},[],{"trials":1887,"activeCount":102},[],{"trials":1889,"activeCount":102},[],{"trials":1891,"activeCount":102},[],{"intervention":57,"totalTrials":133,"cells":1893},{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1905,"PHASE3":1907,"PHASE4":1909,"NA":1911},{"trials":1895,"activeCount":102},[],{"trials":1897,"activeCount":133,"soonestReadout":56},[1898],{"nctId":54,"briefTitle":55,"status":110,"phases":1899,"primaryCompletion":56,"completion":1900,"start":1901,"enrollment":378,"conditions":1902,"interventions":1904},[90],"2026-02","2023-08-18",[1903],"Hepatocellular Carcinoma",[57],{"trials":1906,"activeCount":102},[],{"trials":1908,"activeCount":102},[],{"trials":1910,"activeCount":102},[],{"trials":1912,"activeCount":102},[],{"intervention":1914,"totalTrials":133,"cells":1915},"QPOP category 1",{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1917,"activeCount":102},[],{"trials":1919,"activeCount":102},[],{"trials":1921,"activeCount":102},[],{"trials":1923,"activeCount":102},[],{"trials":1925,"activeCount":102},[],{"trials":1927,"activeCount":133,"soonestReadout":1235},[1928],{"nctId":1929,"briefTitle":1930,"status":110,"phases":1931,"primaryCompletion":1235,"completion":1235,"start":1932,"enrollment":869,"conditions":1933,"interventions":1935},"NCT05532397","Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma",[94],"2023-02-17",[1934],"Glioma, Astrocytic",[1914,1936],"QPOP category 2",{"intervention":1936,"totalTrials":133,"cells":1938},{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1943,"PHASE3":1945,"PHASE4":1947,"NA":1949},{"trials":1940,"activeCount":102},[],{"trials":1942,"activeCount":102},[],{"trials":1944,"activeCount":102},[],{"trials":1946,"activeCount":102},[],{"trials":1948,"activeCount":102},[],{"trials":1950,"activeCount":133,"soonestReadout":1235},[1951],{"nctId":1929,"briefTitle":1930,"status":110,"phases":1952,"primaryCompletion":1235,"completion":1235,"start":1932,"enrollment":869,"conditions":1953,"interventions":1954},[94],[1934],[1914,1936],{"intervention":1956,"totalTrials":133,"cells":1957},"Medical management",{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1964,"PHASE4":1966,"NA":1968},{"trials":1959,"activeCount":102},[],{"trials":1961,"activeCount":102},[],{"trials":1963,"activeCount":102},[],{"trials":1965,"activeCount":102},[],{"trials":1967,"activeCount":102},[],{"trials":1969,"activeCount":133,"soonestReadout":323},[1970],{"nctId":1971,"briefTitle":1972,"status":153,"phases":1973,"primaryCompletion":323,"completion":1974,"start":1975,"enrollment":1976,"conditions":1977,"interventions":1980},"NCT06983795","Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study",[],"2030-12","2025-07",1000,[1978,1979],"Ischemic Stroke","Patent Foramen Ovale",[1956],{"intervention":1982,"totalTrials":478,"cells":1983},"Simvastatin",{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1988,"PHASE3":1998,"PHASE4":2000,"NA":2010},{"trials":1985,"activeCount":102},[],{"trials":1987,"activeCount":102},[],{"trials":1989,"activeCount":102},[1990],{"nctId":1991,"briefTitle":1992,"status":141,"phases":1993,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":378,"conditions":1996,"interventions":1997},"NCT00807950","Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer",[91],"2014-12","2008-03",[15],[1982],{"trials":1999,"activeCount":102},[],{"trials":2001,"activeCount":102},[2002],{"nctId":2003,"briefTitle":2004,"status":141,"phases":2005,"primaryCompletion":1765,"completion":1765,"start":2006,"enrollment":869,"conditions":2007,"interventions":2009},"NCT03571802","Pharmacokinetics of Simvastatin Post Laparoscopic Sleeve Gastrectomy (LSG)",[93],"2018-06-13",[30,2008],"Hyperlipidemias",[1982],{"trials":2011,"activeCount":102},[],{"intervention":2013,"totalTrials":133,"cells":2014},"Syntommetrine and Carbetocin",{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2019,"PHASE3":2021,"PHASE4":2023,"NA":2036},{"trials":2016,"activeCount":102},[],{"trials":2018,"activeCount":102},[],{"trials":2020,"activeCount":102},[],{"trials":2022,"activeCount":102},[],{"trials":2024,"activeCount":102},[2025],{"nctId":2026,"briefTitle":2027,"status":337,"phases":2028,"primaryCompletion":2029,"completion":2030,"start":2031,"enrollment":2032,"conditions":2033,"interventions":2035},"NCT00499005","Carbetocin Versus Syntometrine for the Third Stage of Labour",[93],"2009-04","2009-07","2006-11",720,[2034],"Postpartum Haemorrhage",[2013,2013],{"trials":2037,"activeCount":102},[],{"intervention":2039,"totalTrials":133,"cells":2040},"Rifaximin Oral",{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2047,"PHASE4":2049,"NA":2060},{"trials":2042,"activeCount":102},[],{"trials":2044,"activeCount":102},[],{"trials":2046,"activeCount":102},[],{"trials":2048,"activeCount":102},[],{"trials":2050,"activeCount":102},[2051],{"nctId":2052,"briefTitle":2053,"status":337,"phases":2054,"primaryCompletion":2055,"completion":2055,"start":2056,"enrollment":542,"conditions":2057,"interventions":2059},"NCT03557788","Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome",[93],"2021-08-13","2018-05-07",[2058],"Irritable Bowel Syndrome With Diarrhea",[2039],{"trials":2061,"activeCount":102},[],{"intervention":2063,"totalTrials":133,"cells":2064},"Ferric Carboxymaltose",{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2069,"PHASE3":2071,"PHASE4":2073,"NA":2086},{"trials":2066,"activeCount":102},[],{"trials":2068,"activeCount":102},[],{"trials":2070,"activeCount":102},[],{"trials":2072,"activeCount":102},[],{"trials":2074,"activeCount":102},[2075],{"nctId":2076,"briefTitle":2077,"status":337,"phases":2078,"primaryCompletion":340,"completion":2079,"start":2080,"enrollment":283,"conditions":2081,"interventions":2085},"NCT01922479","Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure",[93],"2015-12","2013-09",[2082,2083,2084],"Heart Failure","Anemia","Iron Deficiency",[2063],{"trials":2087,"activeCount":102},[],{"intervention":2089,"totalTrials":133,"cells":2090},"Escitalopram treatment",{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2097,"PHASE4":2099,"NA":2110},{"trials":2092,"activeCount":102},[],{"trials":2094,"activeCount":102},[],{"trials":2096,"activeCount":102},[],{"trials":2098,"activeCount":102},[],{"trials":2100,"activeCount":102},[2101],{"nctId":2102,"briefTitle":2103,"status":337,"phases":2104,"primaryCompletion":2105,"completion":2105,"start":2106,"enrollment":1633,"conditions":2107,"interventions":2109},"NCT00693732","Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS)",[93],"2012-01","2009-02",[2108],"Irritable Bowel Syndrome",[2089],{"trials":2111,"activeCount":102},[],{"intervention":1703,"totalTrials":133,"cells":2113},{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2120,"PHASE4":2122,"NA":2128},{"trials":2115,"activeCount":102},[],{"trials":2117,"activeCount":102},[],{"trials":2119,"activeCount":102},[],{"trials":2121,"activeCount":102},[],{"trials":2123,"activeCount":102},[2124],{"nctId":1694,"briefTitle":1695,"status":337,"phases":2125,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1699,"conditions":2126,"interventions":2127},[93],[1701],[1672,1703,1704,1705],{"trials":2129,"activeCount":102},[],{"intervention":1704,"totalTrials":133,"cells":2131},{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2138,"PHASE4":2140,"NA":2146},{"trials":2133,"activeCount":102},[],{"trials":2135,"activeCount":102},[],{"trials":2137,"activeCount":102},[],{"trials":2139,"activeCount":102},[],{"trials":2141,"activeCount":102},[2142],{"nctId":1694,"briefTitle":1695,"status":337,"phases":2143,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1699,"conditions":2144,"interventions":2145},[93],[1701],[1672,1703,1704,1705],{"trials":2147,"activeCount":102},[],{"intervention":148,"totalTrials":133,"cells":2149},{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2154,"PHASE3":2156,"PHASE4":2158,"NA":2164},{"trials":2151,"activeCount":102},[],{"trials":2153,"activeCount":102},[],{"trials":2155,"activeCount":102},[],{"trials":2157,"activeCount":102},[],{"trials":2159,"activeCount":102},[2160],{"nctId":139,"briefTitle":140,"status":141,"phases":2161,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":2162,"interventions":2163},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":2165,"activeCount":102},[],{"intervention":149,"totalTrials":133,"cells":2167},{"EARLY_PHASE1":2168,"PHASE1":2170,"PHASE2":2172,"PHASE3":2174,"PHASE4":2176,"NA":2182},{"trials":2169,"activeCount":102},[],{"trials":2171,"activeCount":102},[],{"trials":2173,"activeCount":102},[],{"trials":2175,"activeCount":102},[],{"trials":2177,"activeCount":102},[2178],{"nctId":139,"briefTitle":140,"status":141,"phases":2179,"primaryCompletion":143,"start":144,"enrollment":114,"conditions":2180,"interventions":2181},[93],[146],[97,118,121,119,120,148,131,126,127,149,129,132,125],{"trials":2183,"activeCount":102},[],{"intervention":2185,"totalTrials":133,"cells":2186},"Vaxigrip®",{"EARLY_PHASE1":2187,"PHASE1":2189,"PHASE2":2191,"PHASE3":2193,"PHASE4":2195,"NA":2207},{"trials":2188,"activeCount":102},[],{"trials":2190,"activeCount":102},[],{"trials":2192,"activeCount":102},[],{"trials":2194,"activeCount":102},[],{"trials":2196,"activeCount":102},[2197],{"nctId":2198,"briefTitle":2199,"status":337,"phases":2200,"primaryCompletion":2201,"completion":2201,"start":2202,"enrollment":2203,"conditions":2204,"interventions":2206},"NCT03266237","The Immune Response to Influenza Vaccinations in Elderly Individuals",[93],"2016-05","2013-12",240,[2205],"Influenza",[2185],{"trials":2208,"activeCount":102},[],{"intervention":2210,"totalTrials":133,"cells":2211},"Ketotifen",{"EARLY_PHASE1":2212,"PHASE1":2214,"PHASE2":2216,"PHASE3":2218,"PHASE4":2220,"NA":2234},{"trials":2213,"activeCount":102},[],{"trials":2215,"activeCount":102},[],{"trials":2217,"activeCount":102},[],{"trials":2219,"activeCount":102},[],{"trials":2221,"activeCount":102},[2222],{"nctId":2223,"briefTitle":2224,"status":141,"phases":2225,"primaryCompletion":2226,"completion":2227,"start":2228,"enrollment":2229,"conditions":2230,"interventions":2233},"NCT02673840","Ketotifen as a Treatment for Vascular Leakage During Dengue Fever",[93],"2016-07","2017-07","2015-03",110,[2231,2232],"Dengue Fever","Pleural Effusion",[2210],{"trials":2235,"activeCount":102},[],{"intervention":2237,"totalTrials":133,"cells":2238},"Intravenous acetazolamide",{"EARLY_PHASE1":2239,"PHASE1":2241,"PHASE2":2243,"PHASE3":2245,"PHASE4":2247,"NA":2259},{"trials":2240,"activeCount":102},[],{"trials":2242,"activeCount":102},[],{"trials":2244,"activeCount":102},[],{"trials":2246,"activeCount":102},[],{"trials":2248,"activeCount":102},[2249],{"nctId":2250,"briefTitle":2251,"status":141,"phases":2252,"completion":2253,"start":2254,"enrollment":2255,"conditions":2256,"interventions":2258},"NCT00485238","ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function",[93],"2008-12","2007-02",60,[2257],"Glaucoma",[2237],{"trials":2260,"activeCount":102},[],{"intervention":2262,"totalTrials":133,"cells":2263},"CPT-11, Raltegravir (Isentress®), Midazolam",{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2270,"PHASE4":2272,"NA":2283},{"trials":2265,"activeCount":102},[],{"trials":2267,"activeCount":102},[],{"trials":2269,"activeCount":102},[],{"trials":2271,"activeCount":102},[],{"trials":2273,"activeCount":102},[2274],{"nctId":2275,"briefTitle":2276,"status":337,"phases":2277,"primaryCompletion":2278,"completion":2278,"start":2279,"enrollment":2280,"conditions":2281,"interventions":2282},"NCT00808184","Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype",[93],"2012-02","2010-04",25,[871],[2262],{"trials":2284,"activeCount":102},[],{"intervention":2286,"totalTrials":133,"cells":2287},"Belimumab Injection [Benlysta]",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2296,"NA":2308},{"trials":2289,"activeCount":102},[],{"trials":2291,"activeCount":102},[],{"trials":2293,"activeCount":102},[],{"trials":2295,"activeCount":102},[],{"trials":2297,"activeCount":102},[2298],{"nctId":2299,"briefTitle":2300,"status":141,"phases":2301,"primaryCompletion":2302,"completion":2302,"start":2303,"enrollment":2304,"conditions":2305,"interventions":2307},"NCT04447053","Sequential Belimumab and T-cell Based Therapy in SLE",[93],"2025-05-20","2021-11-08",80,[2306],"Systemic Lupus Erythematosus",[2286],{"trials":2309,"activeCount":102},[],{"intervention":2311,"totalTrials":478,"cells":2312},"Cisplatin",{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2317,"PHASE3":2329,"PHASE4":2338,"NA":2340},{"trials":2314,"activeCount":102},[],{"trials":2316,"activeCount":102},[],{"trials":2318,"activeCount":102},[2319],{"nctId":2320,"briefTitle":2321,"status":141,"phases":2322,"primaryCompletion":2079,"completion":2323,"start":2324,"enrollment":9,"conditions":2325,"interventions":2326},"NCT00674167","The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma",[91],"2017-12","2007-05",[18],[2327,2311,2328],"Docetaxel","Capecitabine",{"trials":2330,"activeCount":102},[2331],{"nctId":2332,"briefTitle":2333,"status":141,"phases":2334,"conditions":2335,"interventions":2337},"NCT00548821","Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer",[92],[2336],"Locally Advanced Cervical Cancer",[2311],{"trials":2339,"activeCount":102},[],{"trials":2341,"activeCount":102},[],{"intervention":2343,"totalTrials":133,"cells":2344},"Regorafenib",{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2351,"PHASE4":2362,"NA":2364},{"trials":2346,"activeCount":102},[],{"trials":2348,"activeCount":102},[],{"trials":2350,"activeCount":102},[],{"trials":2352,"activeCount":102},[2353],{"nctId":2354,"briefTitle":2355,"status":141,"phases":2356,"primaryCompletion":2357,"start":2358,"conditions":2359,"interventions":2361},"NCT01189903","Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients",[91,92],"2013-08","2011-01",[2360],"Asian Colorectal Cancer Patients",[2343],{"trials":2363,"activeCount":102},[],{"trials":2365,"activeCount":102},[],{"intervention":2367,"totalTrials":133,"cells":2368},"Warfarin Sodium",{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2375,"PHASE4":2387,"NA":2389},{"trials":2370,"activeCount":102},[],{"trials":2372,"activeCount":102},[],{"trials":2374,"activeCount":102},[],{"trials":2376,"activeCount":102},[2377],{"nctId":2378,"briefTitle":2379,"status":141,"phases":2380,"primaryCompletion":2381,"completion":806,"start":2382,"enrollment":2383,"conditions":2384,"interventions":2386},"NCT00700895","Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose",[92],"2016-08","2006-08",320,[2385],"Indications for Warfarin Therapy",[2367],{"trials":2388,"activeCount":102},[],{"trials":2390,"activeCount":102},[],{"intervention":2392,"totalTrials":133,"cells":2393},"PCD",{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2398,"PHASE3":2400,"PHASE4":2413,"NA":2415},{"trials":2395,"activeCount":102},[],{"trials":2397,"activeCount":102},[],{"trials":2399,"activeCount":102},[],{"trials":2401,"activeCount":102},[2402],{"nctId":2403,"briefTitle":2404,"status":141,"phases":2405,"primaryCompletion":2406,"completion":2407,"start":2408,"enrollment":575,"conditions":2409,"interventions":2411},"NCT03143049","Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma",[92],"2018-06-01","2022-06-01","2017-09-13",[2410],"Relapse Multiple Myeloma",[2392,2412],"PD",{"trials":2414,"activeCount":102},[],{"trials":2416,"activeCount":102},[],{"intervention":2412,"totalTrials":133,"cells":2418},{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2425,"PHASE4":2431,"NA":2433},{"trials":2420,"activeCount":102},[],{"trials":2422,"activeCount":102},[],{"trials":2424,"activeCount":102},[],{"trials":2426,"activeCount":102},[2427],{"nctId":2403,"briefTitle":2404,"status":141,"phases":2428,"primaryCompletion":2406,"completion":2407,"start":2408,"enrollment":575,"conditions":2429,"interventions":2430},[92],[2410],[2392,2412],{"trials":2432,"activeCount":102},[],{"trials":2434,"activeCount":102},[],{"intervention":2436,"totalTrials":133,"cells":2437},"Hydroxychloroquine Sulfate",{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2442,"PHASE3":2444,"PHASE4":2459,"NA":2461},{"trials":2439,"activeCount":102},[],{"trials":2441,"activeCount":102},[],{"trials":2443,"activeCount":102},[],{"trials":2445,"activeCount":102},[2446],{"nctId":2447,"briefTitle":2448,"status":337,"phases":2449,"primaryCompletion":2450,"completion":2450,"start":2451,"enrollment":2452,"conditions":2453,"interventions":2455},"NCT04446104","A Preventive Treatment for Migrant Workers at High-risk of COVID-19",[92],"2020-08-31","2020-05-13",4257,[2454],"Covid-19",[2436,2456,2457,2458],"Ivermectin 3mg Tab","Zinc","Povidone-Iodine",{"trials":2460,"activeCount":102},[],{"trials":2462,"activeCount":102},[],{"intervention":2456,"totalTrials":133,"cells":2464},{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2471,"PHASE4":2477,"NA":2479},{"trials":2466,"activeCount":102},[],{"trials":2468,"activeCount":102},[],{"trials":2470,"activeCount":102},[],{"trials":2472,"activeCount":102},[2473],{"nctId":2447,"briefTitle":2448,"status":337,"phases":2474,"primaryCompletion":2450,"completion":2450,"start":2451,"enrollment":2452,"conditions":2475,"interventions":2476},[92],[2454],[2436,2456,2457,2458],{"trials":2478,"activeCount":102},[],{"trials":2480,"activeCount":102},[],{"intervention":2457,"totalTrials":133,"cells":2482},{"EARLY_PHASE1":2483,"PHASE1":2485,"PHASE2":2487,"PHASE3":2489,"PHASE4":2495,"NA":2497},{"trials":2484,"activeCount":102},[],{"trials":2486,"activeCount":102},[],{"trials":2488,"activeCount":102},[],{"trials":2490,"activeCount":102},[2491],{"nctId":2447,"briefTitle":2448,"status":337,"phases":2492,"primaryCompletion":2450,"completion":2450,"start":2451,"enrollment":2452,"conditions":2493,"interventions":2494},[92],[2454],[2436,2456,2457,2458],{"trials":2496,"activeCount":102},[],{"trials":2498,"activeCount":102},[],{"intervention":2458,"totalTrials":133,"cells":2500},{"EARLY_PHASE1":2501,"PHASE1":2503,"PHASE2":2505,"PHASE3":2507,"PHASE4":2513,"NA":2515},{"trials":2502,"activeCount":102},[],{"trials":2504,"activeCount":102},[],{"trials":2506,"activeCount":102},[],{"trials":2508,"activeCount":102},[2509],{"nctId":2447,"briefTitle":2448,"status":337,"phases":2510,"primaryCompletion":2450,"completion":2450,"start":2451,"enrollment":2452,"conditions":2511,"interventions":2512},[92],[2454],[2436,2456,2457,2458],{"trials":2514,"activeCount":102},[],{"trials":2516,"activeCount":102},[],{"intervention":2518,"totalTrials":133,"cells":2519},"GCSF",{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2538,"NA":2540},{"trials":2521,"activeCount":102},[],{"trials":2523,"activeCount":102},[],{"trials":2525,"activeCount":102},[],{"trials":2527,"activeCount":102},[2528],{"nctId":2529,"briefTitle":2530,"status":141,"phases":2531,"primaryCompletion":2532,"completion":2533,"start":2534,"enrollment":504,"conditions":2535,"interventions":2537},"NCT03109236","Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis",[92],"2022-12-31","2023-12-31","2017-08-24",[2536],"End Stage Liver Disease",[2518],{"trials":2539,"activeCount":102},[],{"trials":2541,"activeCount":102},[],{"intervention":2543,"totalTrials":133,"cells":2544},"N-acetylcysteine",{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2551,"PHASE4":2564,"NA":2566},{"trials":2546,"activeCount":102},[],{"trials":2548,"activeCount":102},[],{"trials":2550,"activeCount":102},[],{"trials":2552,"activeCount":102},[2553],{"nctId":2554,"briefTitle":2555,"status":337,"phases":2556,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":2559,"conditions":2560,"interventions":2562},"NCT00497328","COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect of contrasT",[91,92],"2013-06","2007-08",477,[2561],"Contrast Induced Nephropathy",[2543,2563],"Sodium Bicarbonate",{"trials":2565,"activeCount":102},[],{"trials":2567,"activeCount":102},[],{"intervention":2563,"totalTrials":133,"cells":2569},{"EARLY_PHASE1":2570,"PHASE1":2572,"PHASE2":2574,"PHASE3":2576,"PHASE4":2582,"NA":2584},{"trials":2571,"activeCount":102},[],{"trials":2573,"activeCount":102},[],{"trials":2575,"activeCount":102},[],{"trials":2577,"activeCount":102},[2578],{"nctId":2554,"briefTitle":2555,"status":337,"phases":2579,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":2559,"conditions":2580,"interventions":2581},[91,92],[2561],[2543,2563],{"trials":2583,"activeCount":102},[],{"trials":2585,"activeCount":102},[],{"intervention":2587,"totalTrials":133,"cells":2588},"Hydralazine",{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2595,"PHASE4":2607,"NA":2609},{"trials":2590,"activeCount":102},[],{"trials":2592,"activeCount":102},[],{"trials":2594,"activeCount":102},[],{"trials":2596,"activeCount":102},[2597],{"nctId":2598,"briefTitle":2599,"status":141,"phases":2600,"primaryCompletion":2079,"completion":2601,"start":2602,"enrollment":378,"conditions":2603,"interventions":2605},"NCT02343393","Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study",[92],"2016-06","2015-01",[2604],"Cardio-Renal Syndrome",[2587,2606],"Isosorbide Dinitrate",{"trials":2608,"activeCount":102},[],{"trials":2610,"activeCount":102},[],{"intervention":2606,"totalTrials":133,"cells":2612},{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2617,"PHASE3":2619,"PHASE4":2625,"NA":2627},{"trials":2614,"activeCount":102},[],{"trials":2616,"activeCount":102},[],{"trials":2618,"activeCount":102},[],{"trials":2620,"activeCount":102},[2621],{"nctId":2598,"briefTitle":2599,"status":141,"phases":2622,"primaryCompletion":2079,"completion":2601,"start":2602,"enrollment":378,"conditions":2623,"interventions":2624},[92],[2604],[2587,2606],{"trials":2626,"activeCount":102},[],{"trials":2628,"activeCount":102},[],{"intervention":2630,"totalTrials":133,"cells":2631},"pregabalin",{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2636,"PHASE3":2638,"PHASE4":2654,"NA":2656},{"trials":2633,"activeCount":102},[],{"trials":2635,"activeCount":102},[],{"trials":2637,"activeCount":102},[],{"trials":2639,"activeCount":102},[2640],{"nctId":2641,"briefTitle":2642,"status":337,"phases":2643,"primaryCompletion":2644,"completion":2644,"start":2645,"enrollment":2646,"conditions":2647,"interventions":2649},"NCT02954484","Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty",[92],"2017-05","2015-04",116,[2648],"Pain, Postoperative",[2630,2650,2651,2652,2653],"Etoricoxib","paracetamol","Morphine","Ropivacaine",{"trials":2655,"activeCount":102},[],{"trials":2657,"activeCount":102},[],{"intervention":2650,"totalTrials":133,"cells":2659},{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2666,"PHASE4":2672,"NA":2674},{"trials":2661,"activeCount":102},[],{"trials":2663,"activeCount":102},[],{"trials":2665,"activeCount":102},[],{"trials":2667,"activeCount":102},[2668],{"nctId":2641,"briefTitle":2642,"status":337,"phases":2669,"primaryCompletion":2644,"completion":2644,"start":2645,"enrollment":2646,"conditions":2670,"interventions":2671},[92],[2648],[2630,2650,2651,2652,2653],{"trials":2673,"activeCount":102},[],{"trials":2675,"activeCount":102},[],{"intervention":2651,"totalTrials":133,"cells":2677},{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2684,"PHASE4":2690,"NA":2692},{"trials":2679,"activeCount":102},[],{"trials":2681,"activeCount":102},[],{"trials":2683,"activeCount":102},[],{"trials":2685,"activeCount":102},[2686],{"nctId":2641,"briefTitle":2642,"status":337,"phases":2687,"primaryCompletion":2644,"completion":2644,"start":2645,"enrollment":2646,"conditions":2688,"interventions":2689},[92],[2648],[2630,2650,2651,2652,2653],{"trials":2691,"activeCount":102},[],{"trials":2693,"activeCount":102},[],{"intervention":2652,"totalTrials":133,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2702,"PHASE4":2708,"NA":2710},{"trials":2697,"activeCount":102},[],{"trials":2699,"activeCount":102},[],{"trials":2701,"activeCount":102},[],{"trials":2703,"activeCount":102},[2704],{"nctId":2641,"briefTitle":2642,"status":337,"phases":2705,"primaryCompletion":2644,"completion":2644,"start":2645,"enrollment":2646,"conditions":2706,"interventions":2707},[92],[2648],[2630,2650,2651,2652,2653],{"trials":2709,"activeCount":102},[],{"trials":2711,"activeCount":102},[],{"intervention":2653,"totalTrials":133,"cells":2713},{"EARLY_PHASE1":2714,"PHASE1":2716,"PHASE2":2718,"PHASE3":2720,"PHASE4":2726,"NA":2728},{"trials":2715,"activeCount":102},[],{"trials":2717,"activeCount":102},[],{"trials":2719,"activeCount":102},[],{"trials":2721,"activeCount":102},[2722],{"nctId":2641,"briefTitle":2642,"status":337,"phases":2723,"primaryCompletion":2644,"completion":2644,"start":2645,"enrollment":2646,"conditions":2724,"interventions":2725},[92],[2648],[2630,2650,2651,2652,2653],{"trials":2727,"activeCount":102},[],{"trials":2729,"activeCount":102},[],{"intervention":2731,"totalTrials":133,"cells":2732},"Bacillus Calmette Guerin and interferon alpha",{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2737,"PHASE3":2739,"PHASE4":2751,"NA":2753},{"trials":2734,"activeCount":102},[],{"trials":2736,"activeCount":102},[],{"trials":2738,"activeCount":102},[],{"trials":2740,"activeCount":102},[2741],{"nctId":2742,"briefTitle":2743,"status":337,"phases":2744,"completion":2745,"start":2746,"enrollment":2747,"conditions":2748,"interventions":2750},"NCT00330707","Combined Use of BCG and Interferon Alpha in Bladder Cancer",[91,92],"2005-06","1995-10",140,[2749],"Carcinoma of Urinary Bladder, Superficial",[2731],{"trials":2752,"activeCount":102},[],{"trials":2754,"activeCount":102},[],{"intervention":522,"totalTrials":133,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2769,"NA":2771},{"trials":2758,"activeCount":102},[],{"trials":2760,"activeCount":102},[],{"trials":2762,"activeCount":102},[],{"trials":2764,"activeCount":102},[2765],{"nctId":514,"briefTitle":515,"status":141,"phases":2766,"primaryCompletion":517,"completion":517,"start":518,"enrollment":473,"conditions":2767,"interventions":2768},[91,92],[520],[522,126,118,523,522,126,523,118,524,524],{"trials":2770,"activeCount":102},[],{"trials":2772,"activeCount":102},[],{"intervention":523,"totalTrials":133,"cells":2774},{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2781,"PHASE4":2787,"NA":2789},{"trials":2776,"activeCount":102},[],{"trials":2778,"activeCount":102},[],{"trials":2780,"activeCount":102},[],{"trials":2782,"activeCount":102},[2783],{"nctId":514,"briefTitle":515,"status":141,"phases":2784,"primaryCompletion":517,"completion":517,"start":518,"enrollment":473,"conditions":2785,"interventions":2786},[91,92],[520],[522,126,118,523,522,126,523,118,524,524],{"trials":2788,"activeCount":102},[],{"trials":2790,"activeCount":102},[],{"intervention":524,"totalTrials":133,"cells":2792},{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2797,"PHASE3":2799,"PHASE4":2805,"NA":2807},{"trials":2794,"activeCount":102},[],{"trials":2796,"activeCount":102},[],{"trials":2798,"activeCount":102},[],{"trials":2800,"activeCount":102},[2801],{"nctId":514,"briefTitle":515,"status":141,"phases":2802,"primaryCompletion":517,"completion":517,"start":518,"enrollment":473,"conditions":2803,"interventions":2804},[91,92],[520],[522,126,118,523,522,126,523,118,524,524],{"trials":2806,"activeCount":102},[],{"trials":2808,"activeCount":102},[],{"intervention":2327,"totalTrials":36,"cells":2810},{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2812,"activeCount":102},[],{"trials":2814,"activeCount":102},[],{"trials":2816,"activeCount":102},[2817,2826,2837,2846,2854,2862],{"nctId":2818,"briefTitle":2819,"status":141,"phases":2820,"primaryCompletion":2821,"completion":2821,"start":2254,"enrollment":2822,"conditions":2823,"interventions":2824},"NCT00669773","Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient",[91],"2014-02",49,[15],[2825,2327],"Adriamycin",{"nctId":2827,"briefTitle":2828,"status":141,"phases":2829,"primaryCompletion":2830,"completion":2831,"start":2832,"enrollment":2304,"conditions":2833,"interventions":2835},"NCT01803503","Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors",[91],"2017-04","2018-04","2013-05",[2834,15,1332,1719,18],"Solid Tumors",[2327,2836],"Sunitinib",{"nctId":2838,"briefTitle":2839,"status":337,"phases":2840,"primaryCompletion":2841,"completion":2841,"start":2842,"enrollment":426,"conditions":2843,"interventions":2844},"NCT00695994","The Effect of Docetaxel or Gemcitabine-based Chemotherapy in East Asian and Caucasian Patients",[91],"2012-09","2006-10",[27,15],[2327,2845],"gemcitabine and carboplatin",{"nctId":2847,"briefTitle":2848,"status":337,"phases":2849,"primaryCompletion":2850,"completion":2278,"start":2851,"enrollment":542,"conditions":2852,"interventions":2853},"NCT00703378","Target Dosing of Docetaxel Through Pharmacokinetic\u002FPharmacodynamic Optimisation of the First Chemotherapeutic Cycle",[90,91],"2011-02","2006-05",[2834],[2327],{"nctId":2855,"briefTitle":2856,"status":337,"phases":2857,"primaryCompletion":2858,"completion":2858,"start":2842,"enrollment":869,"conditions":2859,"interventions":2860},"NCT00697437","Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel",[91],"2013-10",[2834],[2327,2861],"Ketoconazole",{"nctId":2320,"briefTitle":2321,"status":141,"phases":2863,"primaryCompletion":2079,"completion":2323,"start":2324,"enrollment":9,"conditions":2864,"interventions":2865},[91],[18],[2327,2311,2328],{"trials":2867,"activeCount":102},[],{"trials":2869,"activeCount":102},[],{"trials":2871,"activeCount":102},[],{"intervention":2873,"totalTrials":2874,"cells":2875},"Rifampicin",5,{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2908,"PHASE3":2935,"PHASE4":2937,"NA":2939},{"trials":2877,"activeCount":102},[],{"trials":2879,"activeCount":102},[2880,2890,2898],{"nctId":2881,"briefTitle":2882,"status":337,"phases":2883,"primaryCompletion":624,"completion":624,"start":2884,"enrollment":2885,"conditions":2886,"interventions":2887},"NCT02393586","Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin\u002FClavulanic Acid in Healthy Volunteers",[90],"2015-02",43,[32],[2888,2889,2873],"Faropenem","Amoxicillin\u002Fclavulanic acid 500mg\u002F125mg",{"nctId":2891,"briefTitle":2892,"status":2893,"phases":2894,"primaryCompletion":2323,"completion":2323,"start":2884,"enrollment":2895,"conditions":2896,"interventions":2897},"NCT02387242","Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers","SUSPENDED",[90],18,[32],[2873],{"nctId":2899,"briefTitle":2900,"status":337,"phases":2901,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2895,"conditions":2904,"interventions":2905},"NCT02602509","Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers",[90],"2016-02","2015-11",[32],[2906,2873,2907],"Celecoxib","Pyrazinamide",{"trials":2909,"activeCount":102},[2910,2923],{"nctId":2911,"briefTitle":2912,"status":141,"phases":2913,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":2916,"conditions":2917,"interventions":2919},"NCT04504851","Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct",[91],"2021-03-31","2020-08-12",154,[2918],"Pulmonary Tuberculosis",[2920,2873,2921,2907,2922],"Rosuvastatin 10mg","Isoniazid","Ethambutol",{"nctId":2924,"briefTitle":2925,"status":337,"phases":2926,"primaryCompletion":2927,"completion":2928,"start":2929,"enrollment":2930,"conditions":2931,"interventions":2932},"NCT02381470","Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin\u002FClavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers",[91],"2019-09-28","2019-10-02","2019-02-11",58,[2918],[2888,2933,2934,2873],"Amoxicillin\u002Fclavulanic acid","Cefadroxil",{"trials":2936,"activeCount":102},[],{"trials":2938,"activeCount":102},[],{"trials":2940,"activeCount":102},[],{"intervention":2328,"totalTrials":98,"cells":2942},{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2954,"PHASE3":2971,"PHASE4":2973,"NA":2975},{"trials":2944,"activeCount":102},[],{"trials":2946,"activeCount":102},[2947],{"nctId":2948,"briefTitle":2949,"status":337,"phases":2950,"primaryCompletion":1632,"completion":1632,"start":2324,"enrollment":2951,"conditions":2952,"interventions":2953},"NCT00697502","Study of Capecitabine In Patients With Solid Tumors",[90],23,[2834],[2328],{"trials":2955,"activeCount":102},[2956,2967],{"nctId":2957,"briefTitle":2958,"status":141,"phases":2959,"primaryCompletion":2960,"completion":2960,"start":2961,"enrollment":473,"conditions":2962,"interventions":2963},"NCT04522284","PRECISE CURATE.AI Pilot Clinical Trial",[90,91],"2023-08-01","2020-08-20",[871],[2328,2964,2965,2966],"XELOX","XELIRI","Ibrutinib",{"nctId":2320,"briefTitle":2321,"status":141,"phases":2968,"primaryCompletion":2079,"completion":2323,"start":2324,"enrollment":9,"conditions":2969,"interventions":2970},[91],[18],[2327,2311,2328],{"trials":2972,"activeCount":102},[],{"trials":2974,"activeCount":102},[],{"trials":2976,"activeCount":102},[],{"intervention":2907,"totalTrials":98,"cells":2978},{"EARLY_PHASE1":2979,"PHASE1":2981,"PHASE2":2995,"PHASE3":3001,"PHASE4":3003,"NA":3005},{"trials":2980,"activeCount":102},[],{"trials":2982,"activeCount":102},[2983,2991],{"nctId":2984,"briefTitle":2985,"status":337,"phases":2986,"primaryCompletion":2987,"completion":2987,"start":2902,"enrollment":22,"conditions":2988,"interventions":2989},"NCT02700347","Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers",[90],"2016-04",[32],[2907,2990],"Allopurinol",{"nctId":2899,"briefTitle":2900,"status":337,"phases":2992,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2895,"conditions":2993,"interventions":2994},[90],[32],[2906,2873,2907],{"trials":2996,"activeCount":102},[2997],{"nctId":2911,"briefTitle":2912,"status":141,"phases":2998,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":2916,"conditions":2999,"interventions":3000},[91],[2918],[2920,2873,2921,2907,2922],{"trials":3002,"activeCount":102},[],{"trials":3004,"activeCount":102},[],{"trials":3006,"activeCount":102},[],{"intervention":2888,"totalTrials":478,"cells":3008},{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3017,"PHASE3":3023,"PHASE4":3025,"NA":3027},{"trials":3010,"activeCount":102},[],{"trials":3012,"activeCount":102},[3013],{"nctId":2881,"briefTitle":2882,"status":337,"phases":3014,"primaryCompletion":624,"completion":624,"start":2884,"enrollment":2885,"conditions":3015,"interventions":3016},[90],[32],[2888,2889,2873],{"trials":3018,"activeCount":102},[3019],{"nctId":2924,"briefTitle":2925,"status":337,"phases":3020,"primaryCompletion":2927,"completion":2928,"start":2929,"enrollment":2930,"conditions":3021,"interventions":3022},[91],[2918],[2888,2933,2934,2873],{"trials":3024,"activeCount":102},[],{"trials":3026,"activeCount":102},[],{"trials":3028,"activeCount":102},[],{"intervention":3030,"totalTrials":478,"cells":3031},"70% glycolic acid",{"EARLY_PHASE1":3032,"PHASE1":3034,"PHASE2":3036,"PHASE3":3055,"PHASE4":3057,"NA":3059},{"trials":3033,"activeCount":102},[],{"trials":3035,"activeCount":102},[],{"trials":3037,"activeCount":102},[3038,3047],{"nctId":3039,"briefTitle":3040,"status":141,"phases":3041,"primaryCompletion":3042,"completion":3042,"start":3043,"enrollment":869,"conditions":3044,"interventions":3046},"NCT02126657","The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne Scars",[91],"2014-11","2014-05",[3045],"Acne Scars",[3030],{"nctId":3048,"briefTitle":3049,"status":141,"phases":3050,"primaryCompletion":3051,"completion":3051,"start":3043,"enrollment":869,"conditions":3052,"interventions":3054},"NCT02126644","The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging",[91],"2014-09",[3053],"Photoaging",[3030],{"trials":3056,"activeCount":102},[],{"trials":3058,"activeCount":102},[],{"trials":3060,"activeCount":102},[],{"intervention":846,"totalTrials":478,"cells":3062},{"EARLY_PHASE1":3063,"PHASE1":3065,"PHASE2":3078,"PHASE3":3084,"PHASE4":3086,"NA":3088},{"trials":3064,"activeCount":102},[],{"trials":3066,"activeCount":102},[3067],{"nctId":3068,"briefTitle":3069,"status":141,"phases":3070,"primaryCompletion":3071,"completion":3072,"start":3073,"enrollment":157,"conditions":3074,"interventions":3075},"NCT03784040","Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.",[90],"2023-03-01","2024-03-01","2019-02-21",[18],[3076,846,3077],"OTSGC-A24","Ipilimumab",{"trials":3079,"activeCount":102},[3080],{"nctId":837,"briefTitle":838,"status":141,"phases":3081,"primaryCompletion":840,"completion":840,"start":841,"enrollment":842,"conditions":3082,"interventions":3083},[90,91],[844],[846,509],{"trials":3085,"activeCount":102},[],{"trials":3087,"activeCount":102},[],{"trials":3089,"activeCount":102},[],{"intervention":3091,"totalTrials":478,"cells":3092},"MLC901",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3118,"PHASE4":3120,"NA":3122},{"trials":3094,"activeCount":102},[],{"trials":3096,"activeCount":102},[],{"trials":3098,"activeCount":102},[3099,3109],{"nctId":3100,"briefTitle":3101,"status":141,"phases":3102,"primaryCompletion":3103,"completion":3104,"start":3105,"enrollment":351,"conditions":3106,"interventions":3108},"NCT03038035","The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study",[91],"2018-06","2019-06","2016-12",[3107],"Alzheimer Disease",[3091],{"nctId":3110,"briefTitle":3111,"status":337,"phases":3112,"primaryCompletion":2831,"completion":2831,"start":3113,"enrollment":3114,"conditions":3115,"interventions":3117},"NCT01847924","NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects",[91],"2013-03",103,[3116],"Cognitive Impairment",[3091],{"trials":3119,"activeCount":102},[],{"trials":3121,"activeCount":102},[],{"trials":3123,"activeCount":102},[],{"intervention":3076,"totalTrials":478,"cells":3125},{"EARLY_PHASE1":3126,"PHASE1":3128,"PHASE2":3134,"PHASE3":3144,"PHASE4":3146,"NA":3148},{"trials":3127,"activeCount":102},[],{"trials":3129,"activeCount":102},[3130],{"nctId":3068,"briefTitle":3069,"status":141,"phases":3131,"primaryCompletion":3071,"completion":3072,"start":3073,"enrollment":157,"conditions":3132,"interventions":3133},[90],[18],[3076,846,3077],{"trials":3135,"activeCount":102},[3136],{"nctId":3137,"briefTitle":3138,"status":141,"phases":3139,"primaryCompletion":3140,"completion":339,"start":3141,"enrollment":2951,"conditions":3142,"interventions":3143},"NCT01227772","Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer",[90,91],"2016-11","2010-11",[18],[3076],{"trials":3145,"activeCount":102},[],{"trials":3147,"activeCount":102},[],{"trials":3149,"activeCount":102},[],{"intervention":2920,"totalTrials":133,"cells":3151},{"EARLY_PHASE1":3152,"PHASE1":3154,"PHASE2":3156,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3153,"activeCount":102},[],{"trials":3155,"activeCount":102},[],{"trials":3157,"activeCount":102},[3158],{"nctId":2911,"briefTitle":2912,"status":141,"phases":3159,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":2916,"conditions":3160,"interventions":3161},[91],[2918],[2920,2873,2921,2907,2922],{"trials":3163,"activeCount":102},[],{"trials":3165,"activeCount":102},[],{"trials":3167,"activeCount":102},[],{"intervention":2921,"totalTrials":133,"cells":3169},{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3174,"PHASE3":3180,"PHASE4":3182,"NA":3184},{"trials":3171,"activeCount":102},[],{"trials":3173,"activeCount":102},[],{"trials":3175,"activeCount":102},[3176],{"nctId":2911,"briefTitle":2912,"status":141,"phases":3177,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":2916,"conditions":3178,"interventions":3179},[91],[2918],[2920,2873,2921,2907,2922],{"trials":3181,"activeCount":102},[],{"trials":3183,"activeCount":102},[],{"trials":3185,"activeCount":102},[],{"intervention":2922,"totalTrials":133,"cells":3187},{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3192,"PHASE3":3198,"PHASE4":3200,"NA":3202},{"trials":3189,"activeCount":102},[],{"trials":3191,"activeCount":102},[],{"trials":3193,"activeCount":102},[3194],{"nctId":2911,"briefTitle":2912,"status":141,"phases":3195,"primaryCompletion":2914,"completion":2914,"start":2915,"enrollment":2916,"conditions":3196,"interventions":3197},[91],[2918],[2920,2873,2921,2907,2922],{"trials":3199,"activeCount":102},[],{"trials":3201,"activeCount":102},[],{"trials":3203,"activeCount":102},[],{"intervention":3205,"totalTrials":133,"cells":3206},"dabrafenib and trametinib",{"EARLY_PHASE1":3207,"PHASE1":3209,"PHASE2":3211,"PHASE3":3222,"PHASE4":3224,"NA":3226},{"trials":3208,"activeCount":102},[],{"trials":3210,"activeCount":102},[],{"trials":3212,"activeCount":102},[3213],{"nctId":3214,"briefTitle":3215,"status":141,"phases":3216,"primaryCompletion":3217,"completion":3218,"start":3219,"enrollment":2874,"conditions":3220,"interventions":3221},"NCT04554680","Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy",[91],"2021-12","2022-04","2020-12-30",[1578],[3205],{"trials":3223,"activeCount":102},[],{"trials":3225,"activeCount":102},[],{"trials":3227,"activeCount":102},[],{"intervention":3229,"totalTrials":133,"cells":3230},"TAS-102",{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3247,"PHASE4":3249,"NA":3251},{"trials":3232,"activeCount":102},[],{"trials":3234,"activeCount":102},[],{"trials":3236,"activeCount":102},[3237],{"nctId":3238,"briefTitle":3239,"status":141,"phases":3240,"primaryCompletion":3241,"completion":3241,"start":3242,"enrollment":542,"conditions":3243,"interventions":3246},"NCT04627961","A Trial of LONSURF in Recurrent\u002FMetastatic Nasopharyngeal Carcinoma",[91],"2024-10","2020-08-26",[3244,3245],"Metastatic Nasopharyngeal Carcinoma","Recurrent Nasopharyngeal Carcinoma",[3229],{"trials":3248,"activeCount":102},[],{"trials":3250,"activeCount":102},[],{"trials":3252,"activeCount":102},[],{"intervention":3254,"totalTrials":133,"cells":3255},"docetaxel and ketoconazole",{"EARLY_PHASE1":3256,"PHASE1":3258,"PHASE2":3260,"PHASE3":3271,"PHASE4":3273,"NA":3275},{"trials":3257,"activeCount":102},[],{"trials":3259,"activeCount":102},[],{"trials":3261,"activeCount":102},[3262],{"nctId":3263,"briefTitle":3264,"status":337,"phases":3265,"primaryCompletion":3266,"completion":3267,"start":2745,"enrollment":1633,"conditions":3268,"interventions":3270},"NCT00212095","Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer",[91],"2007-04","2012-06",[3269],"Metastatic Breast Cancer",[3254],{"trials":3272,"activeCount":102},[],{"trials":3274,"activeCount":102},[],{"trials":3276,"activeCount":102},[],{"intervention":3278,"totalTrials":133,"cells":3279},"Pomalidomide and Dexamethasone",{"EARLY_PHASE1":3280,"PHASE1":3282,"PHASE2":3284,"PHASE3":3295,"PHASE4":3297,"NA":3299},{"trials":3281,"activeCount":102},[],{"trials":3283,"activeCount":102},[],{"trials":3285,"activeCount":102},[3286],{"nctId":3287,"briefTitle":3288,"status":141,"phases":3289,"primaryCompletion":3290,"completion":3291,"start":3042,"enrollment":378,"conditions":3292,"interventions":3294},"NCT02158702","Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib",[91],"2018-02","2018-11",[520,3293],"Relapse After Use of Lenalidomide and Bortezomib",[3278],{"trials":3296,"activeCount":102},[],{"trials":3298,"activeCount":102},[],{"trials":3300,"activeCount":102},[],{"intervention":3302,"totalTrials":133,"cells":3303},"Spironolactone 25mg",{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3308,"PHASE3":3320,"PHASE4":3322,"NA":3324},{"trials":3305,"activeCount":102},[],{"trials":3307,"activeCount":102},[],{"trials":3309,"activeCount":102},[3310],{"nctId":3311,"briefTitle":3312,"status":141,"phases":3313,"primaryCompletion":3314,"completion":3314,"start":3315,"enrollment":3316,"conditions":3317,"interventions":3319},"NCT04327232","Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study",[91],"2022-05-31","2018-05-23",184,[3318],"Atrial Fibrillation",[3302],{"trials":3321,"activeCount":102},[],{"trials":3323,"activeCount":102},[],{"trials":3325,"activeCount":102},[],{"intervention":3327,"totalTrials":133,"cells":3328},"Daratumumab, thalidomide and dexamethasone",{"EARLY_PHASE1":3329,"PHASE1":3331,"PHASE2":3333,"PHASE3":3345,"PHASE4":3347,"NA":3349},{"trials":3330,"activeCount":102},[],{"trials":3332,"activeCount":102},[],{"trials":3334,"activeCount":102},[3335],{"nctId":3336,"briefTitle":3337,"status":141,"phases":3338,"primaryCompletion":3339,"completion":3340,"start":3341,"enrollment":378,"conditions":3342,"interventions":3344},"NCT03143036","Daratumumab, Thalidomide and Dexamethasone in Relapse and\u002For Refractory Myeloma",[91],"2019-07-01","2022-07-01","2018-05-01",[3343],"Relapse and \u002F or Refractory Myeloma",[3327],{"trials":3346,"activeCount":102},[],{"trials":3348,"activeCount":102},[],{"trials":3350,"activeCount":102},[],{"intervention":3352,"totalTrials":133,"cells":3353},"OPB-111077",{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3358,"PHASE3":3372,"PHASE4":3374,"NA":3376},{"trials":3355,"activeCount":102},[],{"trials":3357,"activeCount":102},[],{"trials":3359,"activeCount":102},[3360],{"nctId":3361,"briefTitle":3362,"status":141,"phases":3363,"primaryCompletion":3364,"completion":3365,"start":3366,"enrollment":3367,"conditions":3368,"interventions":3371},"NCT03158324","Phase IIa Dose-Expansion and Biomarker Study of OPB-111077",[91],"2020-05-22","2020-11-30","2017-05-22",52,[3369,3370],"NPC","Refractory Tumor",[3352],{"trials":3373,"activeCount":102},[],{"trials":3375,"activeCount":102},[],{"trials":3377,"activeCount":102},[],{"intervention":2825,"totalTrials":133,"cells":3379},{"EARLY_PHASE1":3380,"PHASE1":3382,"PHASE2":3384,"PHASE3":3390,"PHASE4":3392,"NA":3394},{"trials":3381,"activeCount":102},[],{"trials":3383,"activeCount":102},[],{"trials":3385,"activeCount":102},[3386],{"nctId":2818,"briefTitle":2819,"status":141,"phases":3387,"primaryCompletion":2821,"completion":2821,"start":2254,"enrollment":2822,"conditions":3388,"interventions":3389},[91],[15],[2825,2327],{"trials":3391,"activeCount":102},[],{"trials":3393,"activeCount":102},[],{"trials":3395,"activeCount":102},[],{"intervention":3397,"totalTrials":133,"cells":3398},"gemcitabine, carboplatin",{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3412,"PHASE4":3414,"NA":3416},{"trials":3400,"activeCount":102},[],{"trials":3402,"activeCount":102},[],{"trials":3404,"activeCount":102},[3405],{"nctId":3406,"briefTitle":3407,"status":337,"phases":3408,"primaryCompletion":3113,"completion":1631,"start":3409,"enrollment":1633,"conditions":3410,"interventions":3411},"NCT00212069","Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer",[91],"2004-03",[3269],[3397],{"trials":3413,"activeCount":102},[],{"trials":3415,"activeCount":102},[],{"trials":3417,"activeCount":102},[],{"intervention":3419,"totalTrials":133,"cells":3420},"IP Paclitaxel",{"EARLY_PHASE1":3421,"PHASE1":3423,"PHASE2":3425,"PHASE3":3435,"PHASE4":3437,"NA":3439},{"trials":3422,"activeCount":102},[],{"trials":3424,"activeCount":102},[],{"trials":3426,"activeCount":102},[3427],{"nctId":3428,"briefTitle":3429,"status":141,"phases":3430,"primaryCompletion":3431,"completion":807,"start":3432,"enrollment":473,"conditions":3433,"interventions":3434},"NCT01739894","Feasibility Study of Intraperitoneal Paclitaxel",[91],"2017-11","2013-01",[18],[3419],{"trials":3436,"activeCount":102},[],{"trials":3438,"activeCount":102},[],{"trials":3440,"activeCount":102},[],{"intervention":2836,"totalTrials":133,"cells":3442},{"EARLY_PHASE1":3443,"PHASE1":3445,"PHASE2":3447,"PHASE3":3453,"PHASE4":3455,"NA":3457},{"trials":3444,"activeCount":102},[],{"trials":3446,"activeCount":102},[],{"trials":3448,"activeCount":102},[3449],{"nctId":2827,"briefTitle":2828,"status":141,"phases":3450,"primaryCompletion":2830,"completion":2831,"start":2832,"enrollment":2304,"conditions":3451,"interventions":3452},[91],[2834,15,1332,1719,18],[2327,2836],{"trials":3454,"activeCount":102},[],{"trials":3456,"activeCount":102},[],{"trials":3458,"activeCount":102},[],{"intervention":3460,"totalTrials":133,"cells":3461},"Capecitabine, Cetuximab, Oxaliplatin",{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3466,"PHASE3":3476,"PHASE4":3478,"NA":3480},{"trials":3463,"activeCount":102},[],{"trials":3465,"activeCount":102},[],{"trials":3467,"activeCount":102},[3468],{"nctId":3469,"briefTitle":3470,"status":141,"phases":3471,"primaryCompletion":1994,"start":3472,"enrollment":1212,"conditions":3473,"interventions":3475},"NCT00795301","A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab",[91],"2008-07",[3474],"Rectal Cancer",[3460],{"trials":3477,"activeCount":102},[],{"trials":3479,"activeCount":102},[],{"trials":3481,"activeCount":102},[],{"intervention":3483,"totalTrials":133,"cells":3484},"Pascolizumab",{"EARLY_PHASE1":3485,"PHASE1":3487,"PHASE2":3489,"PHASE3":3499,"PHASE4":3501,"NA":3503},{"trials":3486,"activeCount":102},[],{"trials":3488,"activeCount":102},[],{"trials":3490,"activeCount":102},[3491],{"nctId":3492,"briefTitle":3493,"status":141,"phases":3494,"primaryCompletion":3495,"completion":2227,"start":3267,"enrollment":1575,"conditions":3496,"interventions":3498},"NCT01638520","Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis",[91],"2017-02",[3497],"Tuberculosis, Pulmonary",[3483],{"trials":3500,"activeCount":102},[],{"trials":3502,"activeCount":102},[],{"trials":3504,"activeCount":102},[],{"intervention":3506,"totalTrials":133,"cells":3507},"Chloroquine",{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3512,"PHASE3":3524,"PHASE4":3526,"NA":3528},{"trials":3509,"activeCount":102},[],{"trials":3511,"activeCount":102},[],{"trials":3513,"activeCount":102},[3514],{"nctId":3515,"briefTitle":3516,"status":141,"phases":3517,"primaryCompletion":3518,"completion":3519,"start":3520,"enrollment":3521,"conditions":3522,"interventions":3523},"NCT01078779","The Chloroquine for Influenza Prevention Trial",[91],"2010-05","2010-08","2009-11",1516,[2205],[3506],{"trials":3525,"activeCount":102},[],{"trials":3527,"activeCount":102},[],{"trials":3529,"activeCount":102},[],{"intervention":3531,"totalTrials":133,"cells":3532},"Expanded , Activated NK cells",{"EARLY_PHASE1":3533,"PHASE1":3535,"PHASE2":3537,"PHASE3":3549,"PHASE4":3551,"NA":3553},{"trials":3534,"activeCount":102},[],{"trials":3536,"activeCount":102},[],{"trials":3538,"activeCount":102},[3539],{"nctId":3540,"briefTitle":3541,"status":141,"phases":3542,"primaryCompletion":3543,"completion":3544,"start":2884,"enrollment":473,"conditions":3545,"interventions":3548},"NCT02409576","Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas",[90,91],"2020-08","2020-09",[3546,3547],"Ewing Sarcoma","Rhabdomyosarcoma",[3531],{"trials":3550,"activeCount":102},[],{"trials":3552,"activeCount":102},[],{"trials":3554,"activeCount":102},[],{"intervention":3556,"totalTrials":133,"cells":3557},"Carfilzomib, Thalidomide and Dexamethasone",{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3572,"PHASE4":3574,"NA":3576},{"trials":3559,"activeCount":102},[],{"trials":3561,"activeCount":102},[],{"trials":3563,"activeCount":102},[3564],{"nctId":3565,"briefTitle":3566,"status":141,"phases":3567,"primaryCompletion":3568,"completion":2407,"start":2408,"enrollment":378,"conditions":3569,"interventions":3571},"NCT03140943","Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and\u002For Refractory Multiple Myeloma",[91],"2019-06-01",[3570],"Relapsed and\u002For Refractory Multiple Myeloma",[3556],{"trials":3573,"activeCount":102},[],{"trials":3575,"activeCount":102},[],{"trials":3577,"activeCount":102},[],{"intervention":3579,"totalTrials":133,"cells":3580},"Lactobacillus Reuteri Oral Solution [BioGaia]",{"EARLY_PHASE1":3581,"PHASE1":3583,"PHASE2":3585,"PHASE3":3598,"PHASE4":3600,"NA":3602},{"trials":3582,"activeCount":102},[],{"trials":3584,"activeCount":102},[],{"trials":3586,"activeCount":102},[3587],{"nctId":3588,"briefTitle":3589,"status":141,"phases":3590,"primaryCompletion":3591,"completion":3592,"start":3593,"enrollment":283,"conditions":3594,"interventions":3596},"NCT03552458","Effects of Probiotics in Preventing Oral Mucositis",[91],"2020-12","2021-06","2018-06-26",[3595],"Head-and-neck Cancer",[3579,3597],"Placebos",{"trials":3599,"activeCount":102},[],{"trials":3601,"activeCount":102},[],{"trials":3603,"activeCount":102},[],{"intervention":3597,"totalTrials":133,"cells":3605},{"EARLY_PHASE1":3606,"PHASE1":3608,"PHASE2":3610,"PHASE3":3616,"PHASE4":3618,"NA":3620},{"trials":3607,"activeCount":102},[],{"trials":3609,"activeCount":102},[],{"trials":3611,"activeCount":102},[3612],{"nctId":3588,"briefTitle":3589,"status":141,"phases":3613,"primaryCompletion":3591,"completion":3592,"start":3593,"enrollment":283,"conditions":3614,"interventions":3615},[91],[3595],[3579,3597],{"trials":3617,"activeCount":102},[],{"trials":3619,"activeCount":102},[],{"trials":3621,"activeCount":102},[],{"intervention":2933,"totalTrials":133,"cells":3623},{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3634,"PHASE4":3636,"NA":3638},{"trials":3625,"activeCount":102},[],{"trials":3627,"activeCount":102},[],{"trials":3629,"activeCount":102},[3630],{"nctId":2924,"briefTitle":2925,"status":337,"phases":3631,"primaryCompletion":2927,"completion":2928,"start":2929,"enrollment":2930,"conditions":3632,"interventions":3633},[91],[2918],[2888,2933,2934,2873],{"trials":3635,"activeCount":102},[],{"trials":3637,"activeCount":102},[],{"trials":3639,"activeCount":102},[],{"intervention":2934,"totalTrials":133,"cells":3641},{"EARLY_PHASE1":3642,"PHASE1":3644,"PHASE2":3646,"PHASE3":3652,"PHASE4":3654,"NA":3656},{"trials":3643,"activeCount":102},[],{"trials":3645,"activeCount":102},[],{"trials":3647,"activeCount":102},[3648],{"nctId":2924,"briefTitle":2925,"status":337,"phases":3649,"primaryCompletion":2927,"completion":2928,"start":2929,"enrollment":2930,"conditions":3650,"interventions":3651},[91],[2918],[2888,2933,2934,2873],{"trials":3653,"activeCount":102},[],{"trials":3655,"activeCount":102},[],{"trials":3657,"activeCount":102},[],{"intervention":3659,"totalTrials":133,"cells":3660},"Nivolumab, Pembrolizumab",{"EARLY_PHASE1":3661,"PHASE1":3663,"PHASE2":3665,"PHASE3":3675,"PHASE4":3677,"NA":3679},{"trials":3662,"activeCount":102},[],{"trials":3664,"activeCount":102},[],{"trials":3666,"activeCount":102},[3667],{"nctId":3668,"briefTitle":3669,"status":141,"phases":3670,"primaryCompletion":3671,"completion":2960,"start":3672,"enrollment":869,"conditions":3673,"interventions":3674},"NCT05175235","Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements",[90,91],"2023-05-31","2021-08-19",[871],[3659],{"trials":3676,"activeCount":102},[],{"trials":3678,"activeCount":102},[],{"trials":3680,"activeCount":102},[],{"intervention":3682,"totalTrials":133,"cells":3683},"Anti-GD2 in combination with NK cells",{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3688,"PHASE3":3700,"PHASE4":3702,"NA":3704},{"trials":3685,"activeCount":102},[],{"trials":3687,"activeCount":102},[],{"trials":3689,"activeCount":102},[3690],{"nctId":3691,"briefTitle":3692,"status":141,"phases":3693,"primaryCompletion":3694,"completion":3695,"start":3696,"enrollment":2874,"conditions":3697,"interventions":3699},"NCT03242603","Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells",[90,91],"2019-08-15","2020-08-15","2017-10-03",[3698],"Neuroblastoma Recurrent",[3682],{"trials":3701,"activeCount":102},[],{"trials":3703,"activeCount":102},[],{"trials":3705,"activeCount":102},[],{"intervention":2845,"totalTrials":133,"cells":3707},{"EARLY_PHASE1":3708,"PHASE1":3710,"PHASE2":3712,"PHASE3":3718,"PHASE4":3720,"NA":3722},{"trials":3709,"activeCount":102},[],{"trials":3711,"activeCount":102},[],{"trials":3713,"activeCount":102},[3714],{"nctId":2838,"briefTitle":2839,"status":337,"phases":3715,"primaryCompletion":2841,"completion":2841,"start":2842,"enrollment":426,"conditions":3716,"interventions":3717},[91],[27,15],[2327,2845],{"trials":3719,"activeCount":102},[],{"trials":3721,"activeCount":102},[],{"trials":3723,"activeCount":102},[],{"intervention":3725,"totalTrials":133,"cells":3726},"Trastuzumab + NK cells",{"EARLY_PHASE1":3727,"PHASE1":3729,"PHASE2":3731,"PHASE3":3741,"PHASE4":3743,"NA":3745},{"trials":3728,"activeCount":102},[],{"trials":3730,"activeCount":102},[],{"trials":3732,"activeCount":102},[3733],{"nctId":3734,"briefTitle":3735,"status":141,"phases":3736,"primaryCompletion":806,"completion":807,"start":3737,"enrollment":3738,"conditions":3739,"interventions":3740},"NCT02030561","NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer",[90,91],"2014-01",29,[15,18],[3725],{"trials":3742,"activeCount":102},[],{"trials":3744,"activeCount":102},[],{"trials":3746,"activeCount":102},[],{"intervention":3748,"totalTrials":133,"cells":3749},"Coriolus Versicolor",{"EARLY_PHASE1":3750,"PHASE1":3752,"PHASE2":3754,"PHASE3":3765,"PHASE4":3767,"NA":3769},{"trials":3751,"activeCount":102},[],{"trials":3753,"activeCount":102},[],{"trials":3755,"activeCount":102},[3756],{"nctId":3757,"briefTitle":3758,"status":3759,"phases":3760,"primaryCompletion":2858,"completion":2858,"start":2279,"enrollment":473,"conditions":3761,"interventions":3764},"NCT01097083","Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma","TERMINATED",[91],[3762,3763],"Carcinoma","Therapy",[3748],{"trials":3766,"activeCount":102},[],{"trials":3768,"activeCount":102},[],{"trials":3770,"activeCount":102},[],{"intervention":3772,"totalTrials":133,"cells":3773},"Vorinostat",{"EARLY_PHASE1":3774,"PHASE1":3776,"PHASE2":3778,"PHASE3":3787,"PHASE4":3789,"NA":3791},{"trials":3775,"activeCount":102},[],{"trials":3777,"activeCount":102},[],{"trials":3779,"activeCount":102},[3780],{"nctId":3781,"briefTitle":3782,"status":141,"phases":3783,"primaryCompletion":2602,"completion":2602,"start":3784,"enrollment":2822,"conditions":3785,"interventions":3786},"NCT00416130","Clinical Trial of SAHA in Patients With Breast Cancer",[90,91],"2007-01",[15],[3772],{"trials":3788,"activeCount":102},[],{"trials":3790,"activeCount":102},[],{"trials":3792,"activeCount":102},[],{"intervention":3794,"totalTrials":133,"cells":3795},"Vinorelbine",{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3797,"activeCount":102},[],{"trials":3799,"activeCount":102},[],{"trials":3801,"activeCount":102},[3802],{"nctId":3803,"briefTitle":3804,"status":141,"phases":3805,"primaryCompletion":3806,"completion":3340,"start":3807,"enrollment":798,"conditions":3808,"interventions":3810},"NCT03188159","Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer",[91],"2021-07-01","2017-07-01",[810,3809],"Fallopian Tube Cancer",[3794],{"trials":3812,"activeCount":102},[],{"trials":3814,"activeCount":102},[],{"trials":3816,"activeCount":102},[],{"intervention":3818,"totalTrials":133,"cells":3819},"Trastuzumab in Combination with TS-ONE and cisplatin",{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3832,"PHASE4":3834,"NA":3836},{"trials":3821,"activeCount":102},[],{"trials":3823,"activeCount":102},[],{"trials":3825,"activeCount":102},[3826],{"nctId":3827,"briefTitle":3828,"status":141,"phases":3829,"primaryCompletion":1994,"completion":3105,"start":2850,"enrollment":1633,"conditions":3830,"interventions":3831},"NCT01228045","A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer",[91],[18],[3818],{"trials":3833,"activeCount":102},[],{"trials":3835,"activeCount":102},[],{"trials":3837,"activeCount":102},[],{"intervention":3839,"totalTrials":133,"cells":3840},"Arm A",{"EARLY_PHASE1":3841,"PHASE1":3843,"PHASE2":3845,"PHASE3":3855,"PHASE4":3857,"NA":3859},{"trials":3842,"activeCount":102},[],{"trials":3844,"activeCount":102},[],{"trials":3846,"activeCount":102},[3847],{"nctId":3848,"briefTitle":3849,"status":141,"phases":3850,"primaryCompletion":3105,"completion":2323,"start":3519,"enrollment":3851,"conditions":3852,"interventions":3853},"NCT01176799","Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor",[91],73,[15],[3839,3854],"Arm B",{"trials":3856,"activeCount":102},[],{"trials":3858,"activeCount":102},[],{"trials":3860,"activeCount":102},[],{"intervention":3854,"totalTrials":133,"cells":3862},{"EARLY_PHASE1":3863,"PHASE1":3865,"PHASE2":3867,"PHASE3":3873,"PHASE4":3875,"NA":3877},{"trials":3864,"activeCount":102},[],{"trials":3866,"activeCount":102},[],{"trials":3868,"activeCount":102},[3869],{"nctId":3848,"briefTitle":3849,"status":141,"phases":3870,"primaryCompletion":3105,"completion":2323,"start":3519,"enrollment":3851,"conditions":3871,"interventions":3872},[91],[15],[3839,3854],{"trials":3874,"activeCount":102},[],{"trials":3876,"activeCount":102},[],{"trials":3878,"activeCount":102},[],{"intervention":3880,"totalTrials":133,"cells":3881},"T-cell therapy + Rituximab + IL-2",{"EARLY_PHASE1":3882,"PHASE1":3884,"PHASE2":3886,"PHASE3":3897,"PHASE4":3899,"NA":3901},{"trials":3883,"activeCount":102},[],{"trials":3885,"activeCount":102},[],{"trials":3887,"activeCount":102},[3888],{"nctId":3889,"briefTitle":3890,"status":141,"phases":3891,"primaryCompletion":2323,"completion":3892,"start":1994,"enrollment":2895,"conditions":3893,"interventions":3896},"NCT02315118","Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies",[90,91],"2018-12",[3894,3895],"B-Cell Chronic Lymphocytic Leukemia","Non-Hodgkin's Lymphoma",[3880],{"trials":3898,"activeCount":102},[],{"trials":3900,"activeCount":102},[],{"trials":3902,"activeCount":102},[],{"intervention":3904,"totalTrials":133,"cells":3905},"Dose-dense doxorubicin\u002Fcyclophosphamide + sunitinib",{"EARLY_PHASE1":3906,"PHASE1":3908,"PHASE2":3910,"PHASE3":3922,"PHASE4":3924,"NA":3926},{"trials":3907,"activeCount":102},[],{"trials":3909,"activeCount":102},[],{"trials":3911,"activeCount":102},[3912],{"nctId":3913,"briefTitle":3914,"status":141,"phases":3915,"primaryCompletion":3916,"completion":3917,"start":2201,"enrollment":3918,"conditions":3919,"interventions":3920},"NCT02790580","Dose-dense Doxorubicin\u002FCyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients",[91],"2020-05","2020-11",98,[15],[3904,3921],"Dose-dense doxorubicin\u002Fcyclophosphamide",{"trials":3923,"activeCount":102},[],{"trials":3925,"activeCount":102},[],{"trials":3927,"activeCount":102},[],{"intervention":3921,"totalTrials":133,"cells":3929},{"EARLY_PHASE1":3930,"PHASE1":3932,"PHASE2":3934,"PHASE3":3940,"PHASE4":3942,"NA":3944},{"trials":3931,"activeCount":102},[],{"trials":3933,"activeCount":102},[],{"trials":3935,"activeCount":102},[3936],{"nctId":3913,"briefTitle":3914,"status":141,"phases":3937,"primaryCompletion":3916,"completion":3917,"start":2201,"enrollment":3918,"conditions":3938,"interventions":3939},[91],[15],[3904,3921],{"trials":3941,"activeCount":102},[],{"trials":3943,"activeCount":102},[],{"trials":3945,"activeCount":102},[],{"intervention":3947,"totalTrials":133,"cells":3948},"TS-1 with cisplatin",{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3953,"PHASE3":3965,"PHASE4":3967,"NA":3969},{"trials":3950,"activeCount":102},[],{"trials":3952,"activeCount":102},[],{"trials":3954,"activeCount":102},[3955],{"nctId":3956,"briefTitle":3957,"status":141,"phases":3958,"primaryCompletion":2323,"completion":3892,"start":3959,"enrollment":3960,"conditions":3961,"interventions":3963},"NCT01100801","A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients",[91],"2010-07",90,[3962],"Recurrent Gastric Cancer",[3947,3964],"TS-1 with oxaliplatin",{"trials":3966,"activeCount":102},[],{"trials":3968,"activeCount":102},[],{"trials":3970,"activeCount":102},[],{"intervention":3964,"totalTrials":133,"cells":3972},{"EARLY_PHASE1":3973,"PHASE1":3975,"PHASE2":3977,"PHASE3":3983,"PHASE4":3985,"NA":3987},{"trials":3974,"activeCount":102},[],{"trials":3976,"activeCount":102},[],{"trials":3978,"activeCount":102},[3979],{"nctId":3956,"briefTitle":3957,"status":141,"phases":3980,"primaryCompletion":2323,"completion":3892,"start":3959,"enrollment":3960,"conditions":3981,"interventions":3982},[91],[3962],[3947,3964],{"trials":3984,"activeCount":102},[],{"trials":3986,"activeCount":102},[],{"trials":3988,"activeCount":102},[],{"intervention":3990,"totalTrials":133,"cells":3991},"Paclitaxel + Carboplatin + ASLAN001",{"EARLY_PHASE1":3992,"PHASE1":3994,"PHASE2":3996,"PHASE3":4007,"PHASE4":4009,"NA":4011},{"trials":3993,"activeCount":102},[],{"trials":3995,"activeCount":102},[],{"trials":3997,"activeCount":102},[3998],{"nctId":3999,"briefTitle":4000,"status":141,"phases":4001,"primaryCompletion":4002,"completion":4003,"start":2228,"enrollment":4004,"conditions":4005,"interventions":4006},"NCT02396108","Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer",[90,91],"2018-03","2019-03",55,[15],[3990],{"trials":4008,"activeCount":102},[],{"trials":4010,"activeCount":102},[],{"trials":4012,"activeCount":102},[],{"intervention":4014,"totalTrials":133,"cells":4015},"durvalumab",{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4020,"PHASE3":4034,"PHASE4":4036,"NA":4038},{"trials":4017,"activeCount":102},[],{"trials":4019,"activeCount":102},[],{"trials":4021,"activeCount":102},[4022],{"nctId":4023,"briefTitle":4024,"status":141,"phases":4025,"primaryCompletion":4026,"completion":4027,"start":4028,"enrollment":4029,"conditions":4030,"interventions":4032},"NCT03405454","A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas",[91],"2021-09-15","2022-03-15","2017-10-09",46,[4031],"Ovarian Clear Cell Carcinoma",[4014,4033],"standard chemotherapy",{"trials":4035,"activeCount":102},[],{"trials":4037,"activeCount":102},[],{"trials":4039,"activeCount":102},[],{"intervention":4033,"totalTrials":133,"cells":4041},{"EARLY_PHASE1":4042,"PHASE1":4044,"PHASE2":4046,"PHASE3":4052,"PHASE4":4054,"NA":4056},{"trials":4043,"activeCount":102},[],{"trials":4045,"activeCount":102},[],{"trials":4047,"activeCount":102},[4048],{"nctId":4023,"briefTitle":4024,"status":141,"phases":4049,"primaryCompletion":4026,"completion":4027,"start":4028,"enrollment":4029,"conditions":4050,"interventions":4051},[91],[4031],[4014,4033],{"trials":4053,"activeCount":102},[],{"trials":4055,"activeCount":102},[],{"trials":4057,"activeCount":102},[],{"intervention":4059,"totalTrials":133,"cells":4060},"Cetuximab + NK cells",{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4065,"PHASE3":4075,"PHASE4":4077,"NA":4079},{"trials":4062,"activeCount":102},[],{"trials":4064,"activeCount":102},[],{"trials":4066,"activeCount":102},[4067],{"nctId":4068,"briefTitle":4069,"status":141,"phases":4070,"primaryCompletion":4071,"completion":4071,"start":4072,"enrollment":16,"conditions":4073,"interventions":4074},"NCT02507154","Reactivating NK Cells in Treating Refractory Head and Neck Cancer",[90,91],"2019-08","2015-07",[1070,1333],[4059],{"trials":4076,"activeCount":102},[],{"trials":4078,"activeCount":102},[],{"trials":4080,"activeCount":102},[],{"intervention":4082,"totalTrials":133,"cells":4083},"paclitaxel\u002Fcarboplatin\u002Flapatinib",{"EARLY_PHASE1":4084,"PHASE1":4086,"PHASE2":4088,"PHASE3":4099,"PHASE4":4101,"NA":4103},{"trials":4085,"activeCount":102},[],{"trials":4087,"activeCount":102},[],{"trials":4089,"activeCount":102},[4090],{"nctId":4091,"briefTitle":4092,"status":141,"phases":4093,"primaryCompletion":1994,"completion":2079,"start":4094,"enrollment":4095,"conditions":4096,"interventions":4098},"NCT01309607","Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer",[91],"2011-04",34,[4097],"ErbB2-Positive Stage I-III Breast Cancer",[4082],{"trials":4100,"activeCount":102},[],{"trials":4102,"activeCount":102},[],{"trials":4104,"activeCount":102},[],{"intervention":4106,"totalTrials":133,"cells":4107},"pembrolizumab and lenvatinib",{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4112,"PHASE3":4125,"PHASE4":4127,"NA":4129},{"trials":4109,"activeCount":102},[],{"trials":4111,"activeCount":102},[],{"trials":4113,"activeCount":102},[4114],{"nctId":4115,"briefTitle":4116,"status":141,"phases":4117,"primaryCompletion":4118,"completion":4119,"start":4120,"enrollment":869,"conditions":4121,"interventions":4124},"NCT04699071","Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)",[91],"2024-01","2025-01","2021-02-18",[4122,4123],"Adenocarcinomas","Recurrent Gynecological",[4106],{"trials":4126,"activeCount":102},[],{"trials":4128,"activeCount":102},[],{"trials":4130,"activeCount":102},[],{"intervention":2964,"totalTrials":133,"cells":4132},{"EARLY_PHASE1":4133,"PHASE1":4135,"PHASE2":4137,"PHASE3":4143,"PHASE4":4145,"NA":4147},{"trials":4134,"activeCount":102},[],{"trials":4136,"activeCount":102},[],{"trials":4138,"activeCount":102},[4139],{"nctId":2957,"briefTitle":2958,"status":141,"phases":4140,"primaryCompletion":2960,"completion":2960,"start":2961,"enrollment":473,"conditions":4141,"interventions":4142},[90,91],[871],[2328,2964,2965,2966],{"trials":4144,"activeCount":102},[],{"trials":4146,"activeCount":102},[],{"trials":4148,"activeCount":102},[],{"intervention":2965,"totalTrials":133,"cells":4150},{"EARLY_PHASE1":4151,"PHASE1":4153,"PHASE2":4155,"PHASE3":4161,"PHASE4":4163,"NA":4165},{"trials":4152,"activeCount":102},[],{"trials":4154,"activeCount":102},[],{"trials":4156,"activeCount":102},[4157],{"nctId":2957,"briefTitle":2958,"status":141,"phases":4158,"primaryCompletion":2960,"completion":2960,"start":2961,"enrollment":473,"conditions":4159,"interventions":4160},[90,91],[871],[2328,2964,2965,2966],{"trials":4162,"activeCount":102},[],{"trials":4164,"activeCount":102},[],{"trials":4166,"activeCount":102},[],{"intervention":2966,"totalTrials":133,"cells":4168},{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4173,"PHASE3":4179,"PHASE4":4181,"NA":4183},{"trials":4170,"activeCount":102},[],{"trials":4172,"activeCount":102},[],{"trials":4174,"activeCount":102},[4175],{"nctId":2957,"briefTitle":2958,"status":141,"phases":4176,"primaryCompletion":2960,"completion":2960,"start":2961,"enrollment":473,"conditions":4177,"interventions":4178},[90,91],[871],[2328,2964,2965,2966],{"trials":4180,"activeCount":102},[],{"trials":4182,"activeCount":102},[],{"trials":4184,"activeCount":102},[],{"intervention":4186,"totalTrials":133,"cells":4187},"12.5mg sunitinib with Cisplatin and Gemcitabine",{"EARLY_PHASE1":4188,"PHASE1":4190,"PHASE2":4192,"PHASE3":4206,"PHASE4":4208,"NA":4210},{"trials":4189,"activeCount":102},[],{"trials":4191,"activeCount":102},[],{"trials":4193,"activeCount":102},[4194],{"nctId":4195,"briefTitle":4196,"status":337,"phases":4197,"primaryCompletion":4198,"completion":4198,"start":4199,"enrollment":2304,"conditions":4200,"interventions":4202},"NCT01309633","Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)",[91],"2019-03-11","2011-09-02",[4201],"Nasopharyngeal Carcinoma",[4186,4203,4204,4205],"25mg Sunitinib alternating with Cisplatin and Gemcitabine","7.5mg\u002Fkg Bevacizumab alternating with Cisplatin and Gemcitabine","2.5mg\u002Fkg Bevacizumab alternating with Cisplatin and Gemcitabine",{"trials":4207,"activeCount":102},[],{"trials":4209,"activeCount":102},[],{"trials":4211,"activeCount":102},[],{"intervention":4203,"totalTrials":133,"cells":4213},{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4218,"PHASE3":4224,"PHASE4":4226,"NA":4228},{"trials":4215,"activeCount":102},[],{"trials":4217,"activeCount":102},[],{"trials":4219,"activeCount":102},[4220],{"nctId":4195,"briefTitle":4196,"status":337,"phases":4221,"primaryCompletion":4198,"completion":4198,"start":4199,"enrollment":2304,"conditions":4222,"interventions":4223},[91],[4201],[4186,4203,4204,4205],{"trials":4225,"activeCount":102},[],{"trials":4227,"activeCount":102},[],{"trials":4229,"activeCount":102},[],{"intervention":4204,"totalTrials":133,"cells":4231},{"EARLY_PHASE1":4232,"PHASE1":4234,"PHASE2":4236,"PHASE3":4242,"PHASE4":4244,"NA":4246},{"trials":4233,"activeCount":102},[],{"trials":4235,"activeCount":102},[],{"trials":4237,"activeCount":102},[4238],{"nctId":4195,"briefTitle":4196,"status":337,"phases":4239,"primaryCompletion":4198,"completion":4198,"start":4199,"enrollment":2304,"conditions":4240,"interventions":4241},[91],[4201],[4186,4203,4204,4205],{"trials":4243,"activeCount":102},[],{"trials":4245,"activeCount":102},[],{"trials":4247,"activeCount":102},[],{"intervention":4205,"totalTrials":133,"cells":4249},{"EARLY_PHASE1":4250,"PHASE1":4252,"PHASE2":4254,"PHASE3":4260,"PHASE4":4262,"NA":4264},{"trials":4251,"activeCount":102},[],{"trials":4253,"activeCount":102},[],{"trials":4255,"activeCount":102},[4256],{"nctId":4195,"briefTitle":4196,"status":337,"phases":4257,"primaryCompletion":4198,"completion":4198,"start":4199,"enrollment":2304,"conditions":4258,"interventions":4259},[91],[4201],[4186,4203,4204,4205],{"trials":4261,"activeCount":102},[],{"trials":4263,"activeCount":102},[],{"trials":4265,"activeCount":102},[],{"intervention":4267,"totalTrials":133,"cells":4268},"Repigel",{"EARLY_PHASE1":4269,"PHASE1":4271,"PHASE2":4273,"PHASE3":4283,"PHASE4":4285,"NA":4287},{"trials":4270,"activeCount":102},[],{"trials":4272,"activeCount":102},[],{"trials":4274,"activeCount":102},[4275],{"nctId":4276,"briefTitle":4277,"status":141,"phases":4278,"primaryCompletion":1994,"completion":1994,"start":4279,"enrollment":1633,"conditions":4280,"interventions":4282},"NCT02126709","The Efficacy and Safety of 3% Povidone-Iodine in Acne Therapy",[91],"2014-06",[4281],"Acne",[4267],{"trials":4284,"activeCount":102},[],{"trials":4286,"activeCount":102},[],{"trials":4288,"activeCount":102},[],{"intervention":4290,"totalTrials":133,"cells":4291},"Citrate 4%",{"EARLY_PHASE1":4292,"PHASE1":4294,"PHASE2":4296,"PHASE3":4310,"PHASE4":4312,"NA":4314},{"trials":4293,"activeCount":102},[],{"trials":4295,"activeCount":102},[],{"trials":4297,"activeCount":102},[4298],{"nctId":4299,"briefTitle":4300,"status":141,"phases":4301,"primaryCompletion":4302,"completion":4303,"start":4304,"enrollment":4305,"conditions":4306,"interventions":4308},"NCT03114722","Citrate 4% Versus Heparinised Saline in Preventing Peripherally Inserted Central Catheter (PICC) Occlusions",[91],"2018-07-31","2018-12-30","2017-07-31",130,[4307],"Occlusion",[4290,4309],"Heparinised saline",{"trials":4311,"activeCount":102},[],{"trials":4313,"activeCount":102},[],{"trials":4315,"activeCount":102},[],{"intervention":4309,"totalTrials":133,"cells":4317},{"EARLY_PHASE1":4318,"PHASE1":4320,"PHASE2":4322,"PHASE3":4328,"PHASE4":4330,"NA":4332},{"trials":4319,"activeCount":102},[],{"trials":4321,"activeCount":102},[],{"trials":4323,"activeCount":102},[4324],{"nctId":4299,"briefTitle":4300,"status":141,"phases":4325,"primaryCompletion":4302,"completion":4303,"start":4304,"enrollment":4305,"conditions":4326,"interventions":4327},[91],[4307],[4290,4309],{"trials":4329,"activeCount":102},[],{"trials":4331,"activeCount":102},[],{"trials":4333,"activeCount":102},[],{"intervention":2861,"totalTrials":133,"cells":4335},{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4340,"PHASE3":4346,"PHASE4":4348,"NA":4350},{"trials":4337,"activeCount":102},[],{"trials":4339,"activeCount":102},[],{"trials":4341,"activeCount":102},[4342],{"nctId":2855,"briefTitle":2856,"status":337,"phases":4343,"primaryCompletion":2858,"completion":2858,"start":2842,"enrollment":869,"conditions":4344,"interventions":4345},[91],[2834],[2327,2861],{"trials":4347,"activeCount":102},[],{"trials":4349,"activeCount":102},[],{"trials":4351,"activeCount":102},[],{"intervention":4353,"totalTrials":133,"cells":4354},"5-Fluorouracil",{"EARLY_PHASE1":4355,"PHASE1":4357,"PHASE2":4359,"PHASE3":4369,"PHASE4":4371,"NA":4373},{"trials":4356,"activeCount":102},[],{"trials":4358,"activeCount":102},[],{"trials":4360,"activeCount":102},[4361],{"nctId":4362,"briefTitle":4363,"status":141,"phases":4364,"primaryCompletion":2601,"completion":339,"start":4365,"enrollment":4004,"conditions":4366,"interventions":4368},"NCT00943137","The Optimization of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer",[91],"2009-06",[4367],"Cancer (Advanced Stage)",[4353],{"trials":4370,"activeCount":102},[],{"trials":4372,"activeCount":102},[],{"trials":4374,"activeCount":102},[],{"intervention":4376,"totalTrials":133,"cells":4377},"carboplatin and gemcitabine",{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4382,"PHASE3":4392,"PHASE4":4394,"NA":4396},{"trials":4379,"activeCount":102},[],{"trials":4381,"activeCount":102},[],{"trials":4383,"activeCount":102},[4384],{"nctId":4385,"briefTitle":4386,"status":337,"phases":4387,"completion":4388,"start":4389,"enrollment":1212,"conditions":4390,"interventions":4391},"NCT00212043","Phase I\u002FII Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma",[91],"2004-02","2000-07",[27],[4376],{"trials":4393,"activeCount":102},[],{"trials":4395,"activeCount":102},[],{"trials":4397,"activeCount":102},[],{"intervention":4399,"totalTrials":133,"cells":4400},"lenvatinib",{"EARLY_PHASE1":4401,"PHASE1":4403,"PHASE2":4405,"PHASE3":4415,"PHASE4":4417,"NA":4419},{"trials":4402,"activeCount":102},[],{"trials":4404,"activeCount":102},[],{"trials":4406,"activeCount":102},[4407],{"nctId":4408,"briefTitle":4409,"status":141,"phases":4410,"primaryCompletion":4411,"completion":4411,"start":4412,"enrollment":1633,"conditions":4413,"interventions":4414},"NCT03168074","Phase II Study of Single Agent Lenvatinib",[91],"2021-03-28","2017-03-28",[15],[4399],{"trials":4416,"activeCount":102},[],{"trials":4418,"activeCount":102},[],{"trials":4420,"activeCount":102},[],{"intervention":4422,"totalTrials":133,"cells":4423},"Metformin\u002FSimvastatin\u002FFulvestrant",{"EARLY_PHASE1":4424,"PHASE1":4426,"PHASE2":4428,"PHASE3":4439,"PHASE4":4441,"NA":4443},{"trials":4425,"activeCount":102},[],{"trials":4427,"activeCount":102},[],{"trials":4429,"activeCount":102},[4430],{"nctId":4431,"briefTitle":4432,"status":141,"phases":4433,"primaryCompletion":4434,"completion":4434,"start":4435,"enrollment":4436,"conditions":4437,"interventions":4438},"NCT03192293","Metformin and Simvastatin in Addition to Fulvestrant",[91],"2019-01-20","2017-01-20",28,[15],[4422],{"trials":4440,"activeCount":102},[],{"trials":4442,"activeCount":102},[],{"trials":4444,"activeCount":102},[],{"intervention":4446,"totalTrials":133,"cells":4447},"L-ergothioneine",{"EARLY_PHASE1":4448,"PHASE1":4450,"PHASE2":4452,"PHASE3":4463,"PHASE4":4465,"NA":4467},{"trials":4449,"activeCount":102},[],{"trials":4451,"activeCount":102},[],{"trials":4453,"activeCount":102},[4454],{"nctId":4455,"briefTitle":4456,"status":337,"phases":4457,"primaryCompletion":2533,"completion":2533,"start":4458,"enrollment":4459,"conditions":4460,"interventions":4462},"NCT03641404","Investigating the Efficacy of Ergothioneine to Delay Cognitive Decline (Pilot)",[90,91],"2019-08-01",19,[4461],"Mild Cognitive Impairment",[4446],{"trials":4464,"activeCount":102},[],{"trials":4466,"activeCount":102},[],{"trials":4468,"activeCount":102},[],{"intervention":4470,"totalTrials":133,"cells":4471},"ASLAN001",{"EARLY_PHASE1":4472,"PHASE1":4474,"PHASE2":4476,"PHASE3":4489,"PHASE4":4491,"NA":4493},{"trials":4473,"activeCount":102},[],{"trials":4475,"activeCount":102},[],{"trials":4477,"activeCount":102},[4478],{"nctId":4479,"briefTitle":4480,"status":141,"phases":4481,"primaryCompletion":4482,"completion":4483,"start":4484,"enrollment":4485,"conditions":4486,"interventions":4488},"NCT03499626","Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced\u002F Metastatic Hepatocellular Carcinoma (HCC)",[90,91],"2019-05-05","2021-05-05","2017-05-05",22,[4487],"Advanced\u002F Metastatic Hepatocellular Carcinoma",[4470],{"trials":4490,"activeCount":102},[],{"trials":4492,"activeCount":102},[],{"trials":4494,"activeCount":102},[],{"intervention":4496,"totalTrials":133,"cells":4497},"doxorubicin, docetaxel",{"EARLY_PHASE1":4498,"PHASE1":4500,"PHASE2":4502,"PHASE3":4511,"PHASE4":4513,"NA":4515},{"trials":4499,"activeCount":102},[],{"trials":4501,"activeCount":102},[],{"trials":4503,"activeCount":102},[4504],{"nctId":4505,"briefTitle":4506,"status":337,"phases":4507,"start":4508,"enrollment":378,"conditions":4509,"interventions":4510},"NCT00212082","Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer",[91],"2002-04",[3269],[4496],{"trials":4512,"activeCount":102},[],{"trials":4514,"activeCount":102},[],{"trials":4516,"activeCount":102},[],{"intervention":4518,"totalTrials":133,"cells":4519},"Docetaxel, Carboplatin",{"EARLY_PHASE1":4520,"PHASE1":4522,"PHASE2":4524,"PHASE3":4533,"PHASE4":4535,"NA":4537},{"trials":4521,"activeCount":102},[],{"trials":4523,"activeCount":102},[],{"trials":4525,"activeCount":102},[4526],{"nctId":4527,"briefTitle":4528,"status":337,"phases":4529,"primaryCompletion":3518,"completion":3518,"start":2324,"enrollment":478,"conditions":4530,"interventions":4532},"NCT00675545","A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients",[91],[4531],"Hormone-Refractory Prostate Cancer",[4518],{"trials":4534,"activeCount":102},[],{"trials":4536,"activeCount":102},[],{"trials":4538,"activeCount":102},[],{"intervention":4540,"totalTrials":133,"cells":4541},"AZD9291",{"EARLY_PHASE1":4542,"PHASE1":4544,"PHASE2":4546,"PHASE3":4559,"PHASE4":4561,"NA":4563},{"trials":4543,"activeCount":102},[],{"trials":4545,"activeCount":102},[],{"trials":4547,"activeCount":102},[4548],{"nctId":4549,"briefTitle":4550,"status":141,"phases":4551,"primaryCompletion":4552,"completion":4553,"start":4554,"enrollment":4555,"conditions":4556,"interventions":4558},"NCT02811354","Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA",[91],"2019-02-24","2020-02-24","2017-02-24",108,[4557],"Carcinoma, Non-Small-Cell Lung",[4540],{"trials":4560,"activeCount":102},[],{"trials":4562,"activeCount":102},[],{"trials":4564,"activeCount":102},[],{"intervention":4566,"totalTrials":133,"cells":4567},"Gefitinib, Hydroxychloroquine",{"EARLY_PHASE1":4568,"PHASE1":4570,"PHASE2":4572,"PHASE3":4582,"PHASE4":4584,"NA":4586},{"trials":4569,"activeCount":102},[],{"trials":4571,"activeCount":102},[],{"trials":4573,"activeCount":102},[4574],{"nctId":4575,"briefTitle":4576,"status":141,"phases":4577,"primaryCompletion":3042,"completion":3042,"start":4578,"enrollment":4579,"conditions":4580,"interventions":4581},"NCT00809237","Hydroxychloroquine and Gefitinib to Treat Lung Cancer",[90,91],"2008-11",71,[1332],[4566],{"trials":4583,"activeCount":102},[],{"trials":4585,"activeCount":102},[],{"trials":4587,"activeCount":102},[],{"intervention":4589,"totalTrials":133,"cells":4590},"celecoxib, gefitinib",{"EARLY_PHASE1":4591,"PHASE1":4593,"PHASE2":4595,"PHASE3":4606,"PHASE4":4608,"NA":4610},{"trials":4592,"activeCount":102},[],{"trials":4594,"activeCount":102},[],{"trials":4596,"activeCount":102},[4597],{"nctId":4598,"briefTitle":4599,"status":337,"phases":4600,"primaryCompletion":4601,"completion":4602,"start":4603,"enrollment":4485,"conditions":4604,"interventions":4605},"NCT00212108","A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839",[90,91],"2007-03","2009-01","2003-11",[4201],[4589],{"trials":4607,"activeCount":102},[],{"trials":4609,"activeCount":102},[],{"trials":4611,"activeCount":102},[],{"intervention":4613,"totalTrials":133,"cells":4614},"KPT-330",{"EARLY_PHASE1":4615,"PHASE1":4617,"PHASE2":4626,"PHASE3":4628,"PHASE4":4630,"NA":4632},{"trials":4616,"activeCount":102},[],{"trials":4618,"activeCount":102},[4619],{"nctId":4620,"briefTitle":4621,"status":337,"phases":4622,"primaryCompletion":4623,"completion":4623,"start":2821,"enrollment":575,"conditions":4624,"interventions":4625},"NCT02078349","Phase I Study of KPT330 in Asian Patients",[90],"2020-03-20",[2834],[4613],{"trials":4627,"activeCount":102},[],{"trials":4629,"activeCount":102},[],{"trials":4631,"activeCount":102},[],{"trials":4633,"activeCount":102},[],{"intervention":4635,"totalTrials":133,"cells":4636},"TS-ONE, Cisplatin, RAD001",{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4647,"PHASE3":4649,"PHASE4":4651,"NA":4653},{"trials":4638,"activeCount":102},[],{"trials":4640,"activeCount":102},[4641],{"nctId":4642,"briefTitle":4643,"status":3759,"phases":4644,"primaryCompletion":2841,"enrollment":1237,"conditions":4645,"interventions":4646},"NCT01096199","A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)",[90],[24],[4635],{"trials":4648,"activeCount":102},[],{"trials":4650,"activeCount":102},[],{"trials":4652,"activeCount":102},[],{"trials":4654,"activeCount":102},[],{"intervention":4656,"totalTrials":133,"cells":4657},"Epimedium Prenylflavonoids Extract",{"EARLY_PHASE1":4658,"PHASE1":4660,"PHASE2":4673,"PHASE3":4675,"PHASE4":4677,"NA":4679},{"trials":4659,"activeCount":102},[],{"trials":4661,"activeCount":102},[4662],{"nctId":4663,"briefTitle":4664,"status":141,"phases":4665,"primaryCompletion":4666,"completion":4667,"start":4668,"enrollment":1633,"conditions":4669,"interventions":4672},"NCT02931305","Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease",[90],"2017-01","2017-10","2016-10",[4670,4671],"Osteoporosis","Cardiovascular Disease",[4656],{"trials":4674,"activeCount":102},[],{"trials":4676,"activeCount":102},[],{"trials":4678,"activeCount":102},[],{"trials":4680,"activeCount":102},[],{"intervention":2990,"totalTrials":133,"cells":4682},{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4691,"PHASE3":4693,"PHASE4":4695,"NA":4697},{"trials":4684,"activeCount":102},[],{"trials":4686,"activeCount":102},[4687],{"nctId":2984,"briefTitle":2985,"status":337,"phases":4688,"primaryCompletion":2987,"completion":2987,"start":2902,"enrollment":22,"conditions":4689,"interventions":4690},[90],[32],[2907,2990],{"trials":4692,"activeCount":102},[],{"trials":4694,"activeCount":102},[],{"trials":4696,"activeCount":102},[],{"trials":4698,"activeCount":102},[],{"intervention":4700,"totalTrials":133,"cells":4701},"Selinexor in combination with nivolumab and ipilimumab",{"EARLY_PHASE1":4702,"PHASE1":4704,"PHASE2":4717,"PHASE3":4719,"PHASE4":4721,"NA":4723},{"trials":4703,"activeCount":102},[],{"trials":4705,"activeCount":102},[4706],{"nctId":4707,"briefTitle":4708,"status":337,"phases":4709,"primaryCompletion":4710,"completion":4710,"start":4711,"enrollment":4712,"conditions":4713,"interventions":4716},"NCT04850755","A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced\u002FMetastatic Solid Malignancies",[90],"2025-03-17","2021-03-08",11,[4714,4715],"Advance Solid Malignancies","Metastatic Solid Malignancies",[4700],{"trials":4718,"activeCount":102},[],{"trials":4720,"activeCount":102},[],{"trials":4722,"activeCount":102},[],{"trials":4724,"activeCount":102},[],{"intervention":4726,"totalTrials":133,"cells":4727},"Autologous cord blood",{"EARLY_PHASE1":4728,"PHASE1":4730,"PHASE2":4740,"PHASE3":4742,"PHASE4":4744,"NA":4746},{"trials":4729,"activeCount":102},[],{"trials":4731,"activeCount":102},[4732],{"nctId":4733,"briefTitle":4734,"status":337,"phases":4735,"primaryCompletion":625,"completion":2903,"start":4736,"enrollment":478,"conditions":4737,"interventions":4739},"NCT01649648","Autologous Cord Blood Cells for Brain Injury in Term Newborns",[90],"2011-09",[4738],"Hypoxic Ischemic Encephalopathy",[4726],{"trials":4741,"activeCount":102},[],{"trials":4743,"activeCount":102},[],{"trials":4745,"activeCount":102},[],{"trials":4747,"activeCount":102},[],{"intervention":4749,"totalTrials":133,"cells":4750},"Glyceryl Tridecanoate",{"EARLY_PHASE1":4751,"PHASE1":4753,"PHASE2":4766,"PHASE3":4768,"PHASE4":4770,"NA":4772},{"trials":4752,"activeCount":102},[],{"trials":4754,"activeCount":102},[4755],{"nctId":4756,"briefTitle":4757,"status":4758,"phases":4759,"primaryCompletion":4760,"completion":4761,"start":4762,"enrollment":102,"conditions":4763,"interventions":4765},"NCT03255889","Absorption and Tolerability Studies of an Emulsion Containing the Coconut Oil-derived Glycerol Tridecanoate in Healthy Men","WITHDRAWN",[90],"2017-09-24","2018-03-28","2017-08-28",[4764],"Polycystic Ovary Syndrome",[4749],{"trials":4767,"activeCount":102},[],{"trials":4769,"activeCount":102},[],{"trials":4771,"activeCount":102},[],{"trials":4773,"activeCount":102},[],{"intervention":4775,"totalTrials":133,"cells":4776},"OPB-51602",{"EARLY_PHASE1":4777,"PHASE1":4779,"PHASE2":4788,"PHASE3":4790,"PHASE4":4792,"NA":4794},{"trials":4778,"activeCount":102},[],{"trials":4780,"activeCount":102},[4781],{"nctId":4782,"briefTitle":4783,"status":3759,"phases":4784,"primaryCompletion":4785,"completion":4785,"start":625,"enrollment":25,"conditions":4786,"interventions":4787},"NCT02058017","OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy",[90],"2015-05",[4201],[4775],{"trials":4789,"activeCount":102},[],{"trials":4791,"activeCount":102},[],{"trials":4793,"activeCount":102},[],{"trials":4795,"activeCount":102},[],{"intervention":4797,"totalTrials":133,"cells":4798},"CD137L-DC-EBV-VAX",{"EARLY_PHASE1":4799,"PHASE1":4801,"PHASE2":4811,"PHASE3":4813,"PHASE4":4815,"NA":4817},{"trials":4800,"activeCount":102},[],{"trials":4802,"activeCount":102},[4803],{"nctId":4804,"briefTitle":4805,"status":141,"phases":4806,"primaryCompletion":1449,"completion":4807,"start":4808,"enrollment":4004,"conditions":4809,"interventions":4810},"NCT03282617","Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent\u002FMetastatic Nasopharyngeal Carcinoma",[90],"2020-08-14","2017-08-14",[1070],[4797],{"trials":4812,"activeCount":102},[],{"trials":4814,"activeCount":102},[],{"trials":4816,"activeCount":102},[],{"trials":4818,"activeCount":102},[],{"intervention":2889,"totalTrials":133,"cells":4820},{"EARLY_PHASE1":4821,"PHASE1":4823,"PHASE2":4829,"PHASE3":4831,"PHASE4":4833,"NA":4835},{"trials":4822,"activeCount":102},[],{"trials":4824,"activeCount":102},[4825],{"nctId":2881,"briefTitle":2882,"status":337,"phases":4826,"primaryCompletion":624,"completion":624,"start":2884,"enrollment":2885,"conditions":4827,"interventions":4828},[90],[32],[2888,2889,2873],{"trials":4830,"activeCount":102},[],{"trials":4832,"activeCount":102},[],{"trials":4834,"activeCount":102},[],{"trials":4836,"activeCount":102},[],{"intervention":4838,"totalTrials":133,"cells":4839},"Device: Pulsed electromagnetic fields (PEMFs); Drug: Anthracycline OR Taxane",{"EARLY_PHASE1":4840,"PHASE1":4842,"PHASE2":4853,"PHASE3":4855,"PHASE4":4857,"NA":4859},{"trials":4841,"activeCount":102},[],{"trials":4843,"activeCount":102},[4844],{"nctId":4845,"briefTitle":4846,"status":337,"phases":4847,"primaryCompletion":4848,"completion":4848,"start":4849,"enrollment":4850,"conditions":4851,"interventions":4852},"NCT06332508","Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)",[90],"2025-08-08","2022-12-30",14,[15],[4838],{"trials":4854,"activeCount":102},[],{"trials":4856,"activeCount":102},[],{"trials":4858,"activeCount":102},[],{"trials":4860,"activeCount":102},[],{"intervention":4862,"totalTrials":133,"cells":4863},"NK cells",{"EARLY_PHASE1":4864,"PHASE1":4866,"PHASE2":4878,"PHASE3":4880,"PHASE4":4882,"NA":4884},{"trials":4865,"activeCount":102},[],{"trials":4867,"activeCount":102},[4868],{"nctId":4869,"briefTitle":4870,"status":141,"phases":4871,"primaryCompletion":3544,"completion":4872,"start":4873,"enrollment":473,"conditions":4874,"interventions":4877},"NCT02123836","Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome",[90],"2020-10","2014-04",[4875,4876],"Acute Leukaemia","Myelodysplastic Syndrome",[4862],{"trials":4879,"activeCount":102},[],{"trials":4881,"activeCount":102},[],{"trials":4883,"activeCount":102},[],{"trials":4885,"activeCount":102},[],{"intervention":4887,"totalTrials":133,"cells":4888},"DAA-I",{"EARLY_PHASE1":4889,"PHASE1":4891,"PHASE2":4900,"PHASE3":4902,"PHASE4":4904,"NA":4906},{"trials":4890,"activeCount":102},[],{"trials":4892,"activeCount":102},[4893],{"nctId":4894,"briefTitle":4895,"status":337,"phases":4896,"primaryCompletion":2079,"completion":2079,"start":340,"enrollment":2895,"conditions":4897,"interventions":4899},"NCT02666196","A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered DAA-I in Healthy Subjects",[90],[4898],"Healthy",[4887],{"trials":4901,"activeCount":102},[],{"trials":4903,"activeCount":102},[],{"trials":4905,"activeCount":102},[],{"trials":4907,"activeCount":102},[],{"intervention":4909,"totalTrials":133,"cells":4910},"Oxaliplatin",{"EARLY_PHASE1":4911,"PHASE1":4913,"PHASE2":4924,"PHASE3":4926,"PHASE4":4928,"NA":4930},{"trials":4912,"activeCount":102},[],{"trials":4914,"activeCount":102},[4915],{"nctId":4916,"briefTitle":4917,"status":141,"phases":4918,"primaryCompletion":4919,"completion":4919,"start":4920,"enrollment":9,"conditions":4921,"interventions":4922},"NCT03172416","Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis",[90],"2024-12-31","2017-04-12",[800],[4909,4923],"Oxaliplatin & Nivolumab",{"trials":4925,"activeCount":102},[],{"trials":4927,"activeCount":102},[],{"trials":4929,"activeCount":102},[],{"trials":4931,"activeCount":102},[],{"intervention":4923,"totalTrials":133,"cells":4933},{"EARLY_PHASE1":4934,"PHASE1":4936,"PHASE2":4942,"PHASE3":4944,"PHASE4":4946,"NA":4948},{"trials":4935,"activeCount":102},[],{"trials":4937,"activeCount":102},[4938],{"nctId":4916,"briefTitle":4917,"status":141,"phases":4939,"primaryCompletion":4919,"completion":4919,"start":4920,"enrollment":9,"conditions":4940,"interventions":4941},[90],[800],[4909,4923],{"trials":4943,"activeCount":102},[],{"trials":4945,"activeCount":102},[],{"trials":4947,"activeCount":102},[],{"trials":4949,"activeCount":102},[],{"intervention":2906,"totalTrials":133,"cells":4951},{"EARLY_PHASE1":4952,"PHASE1":4954,"PHASE2":4960,"PHASE3":4962,"PHASE4":4964,"NA":4966},{"trials":4953,"activeCount":102},[],{"trials":4955,"activeCount":102},[4956],{"nctId":2899,"briefTitle":2900,"status":337,"phases":4957,"primaryCompletion":2902,"completion":2902,"start":2903,"enrollment":2895,"conditions":4958,"interventions":4959},[90],[32],[2906,2873,2907],{"trials":4961,"activeCount":102},[],{"trials":4963,"activeCount":102},[],{"trials":4965,"activeCount":102},[],{"trials":4967,"activeCount":102},[],{"intervention":4969,"totalTrials":133,"cells":4970},"Topotecan",{"EARLY_PHASE1":4971,"PHASE1":4973,"PHASE2":4985,"PHASE3":4987,"PHASE4":4989,"NA":4991},{"trials":4972,"activeCount":102},[],{"trials":4974,"activeCount":102},[4975],{"nctId":4976,"briefTitle":4977,"status":141,"phases":4978,"primaryCompletion":4979,"completion":4980,"start":4981,"enrollment":808,"conditions":4982,"interventions":4984},"NCT05083000","Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care",[90],"2021-12-31","2022-03-31","2021-08-16",[4983],"COVID-19 Respiratory Infection",[4969],{"trials":4986,"activeCount":102},[],{"trials":4988,"activeCount":102},[],{"trials":4990,"activeCount":102},[],{"trials":4992,"activeCount":102},[],{"intervention":3077,"totalTrials":133,"cells":4994},{"EARLY_PHASE1":4995,"PHASE1":4997,"PHASE2":5003,"PHASE3":5005,"PHASE4":5007,"NA":5009},{"trials":4996,"activeCount":102},[],{"trials":4998,"activeCount":102},[4999],{"nctId":3068,"briefTitle":3069,"status":141,"phases":5000,"primaryCompletion":3071,"completion":3072,"start":3073,"enrollment":157,"conditions":5001,"interventions":5002},[90],[18],[3076,846,3077],{"trials":5004,"activeCount":102},[],{"trials":5006,"activeCount":102},[],{"trials":5008,"activeCount":102},[],{"trials":5010,"activeCount":102},[],{"intervention":5012,"totalTrials":133,"cells":5013},"Interleukin, NK cells",{"EARLY_PHASE1":5014,"PHASE1":5016,"PHASE2":5025,"PHASE3":5027,"PHASE4":5029,"NA":5031},{"trials":5015,"activeCount":102},[],{"trials":5017,"activeCount":102},[5018],{"nctId":5019,"briefTitle":5020,"status":337,"phases":5021,"start":2324,"conditions":5022,"interventions":5024},"NCT00717184","A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma",[90],[5023],"Metastatic Nasopharyngeal",[5012],{"trials":5026,"activeCount":102},[],{"trials":5028,"activeCount":102},[],{"trials":5030,"activeCount":102},[],{"trials":5032,"activeCount":102},[],{"intervention":5034,"totalTrials":133,"cells":5035},"Tamsulosin",{"EARLY_PHASE1":5036,"PHASE1":5048,"PHASE2":5050,"PHASE3":5052,"PHASE4":5054,"NA":5056},{"trials":5037,"activeCount":102},[5038],{"nctId":5039,"briefTitle":5040,"status":141,"phases":5041,"primaryCompletion":5042,"completion":3568,"start":5043,"enrollment":426,"conditions":5044,"interventions":5047},"NCT03314259","Prophylactic Alpha-blockers in the Prevention of Urinary Retention Post Inguinal Hernia Repair",[89],"2018-12-01","2017-12-01",[5045,5046],"Urinary Retention","Inguinal Hernia",[5034],{"trials":5049,"activeCount":102},[],{"trials":5051,"activeCount":102},[],{"trials":5053,"activeCount":102},[],{"trials":5055,"activeCount":102},[],{"trials":5057,"activeCount":102},[],{"intervention":5059,"totalTrials":478,"cells":5060},"Afatinib",{"EARLY_PHASE1":5061,"PHASE1":5063,"PHASE2":5065,"PHASE3":5075,"PHASE4":5077,"NA":5079},{"trials":5062,"activeCount":102},[],{"trials":5064,"activeCount":102},[],{"trials":5066,"activeCount":102},[5067],{"nctId":5068,"briefTitle":5069,"status":141,"phases":5070,"primaryCompletion":5071,"completion":5071,"start":3544,"enrollment":473,"conditions":5072,"interventions":5074},"NCT04533321","A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma",[91],"2023-09",[5073],"Squamous Cell Carcinoma",[5059],{"trials":5076,"activeCount":102},[],{"trials":5078,"activeCount":102},[],{"trials":5080,"activeCount":102},[5081],{"nctId":5082,"briefTitle":5083,"status":141,"phases":5084,"primaryCompletion":5085,"completion":61,"start":5086,"enrollment":5087,"conditions":5088,"interventions":5091},"NCT04909073","Observational Study of Afatinib 30 mg Daily",[],"2025-05","2022-10-25",69,[5089,5090],"Non-Small Cell Lung Cancer","Epidermal Growth Factor Receptor Mutation",[5059],{"intervention":5093,"totalTrials":478,"cells":5094},"Blood collection",{"EARLY_PHASE1":5095,"PHASE1":5097,"PHASE2":5099,"PHASE3":5101,"PHASE4":5103,"NA":5105},{"trials":5096,"activeCount":102},[],{"trials":5098,"activeCount":102},[],{"trials":5100,"activeCount":102},[],{"trials":5102,"activeCount":102},[],{"trials":5104,"activeCount":102},[],{"trials":5106,"activeCount":102},[5107,5113],{"nctId":5108,"briefTitle":5109,"status":141,"phases":5110,"primaryCompletion":1994,"completion":1994,"start":2080,"conditions":5111,"interventions":5112},"NCT01050920","Study of Genetic Factors Other Than CYP2C9 and VKORC1 That Influence Warfarin Dose Requirements in a South-east Asian Population",[],[24],[5093],{"nctId":5114,"briefTitle":5115,"status":141,"phases":5116,"primaryCompletion":2079,"completion":2079,"start":2029,"enrollment":5117,"conditions":5118,"interventions":5119},"NCT00941200","Pharmacogenetic DNA Bank",[],5000,[24],[5093],{"intervention":1705,"totalTrials":478,"cells":5121},{"EARLY_PHASE1":5122,"PHASE1":5124,"PHASE2":5126,"PHASE3":5128,"PHASE4":5130,"NA":5136},{"trials":5123,"activeCount":102},[],{"trials":5125,"activeCount":102},[],{"trials":5127,"activeCount":102},[],{"trials":5129,"activeCount":102},[],{"trials":5131,"activeCount":102},[5132],{"nctId":1694,"briefTitle":1695,"status":337,"phases":5133,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1699,"conditions":5134,"interventions":5135},[93],[1701],[1672,1703,1704,1705],{"trials":5137,"activeCount":102},[5138],{"nctId":5139,"briefTitle":5140,"status":141,"phases":5141,"primaryCompletion":3051,"completion":3051,"start":3519,"enrollment":2255,"conditions":5142,"interventions":5144},"NCT01173068","An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.",[],[5143],"Urinary Tract Infections",[1705],{"intervention":5146,"totalTrials":478,"cells":5147},"Metoclopramide",{"EARLY_PHASE1":5148,"PHASE1":5150,"PHASE2":5152,"PHASE3":5154,"PHASE4":5167,"NA":5169},{"trials":5149,"activeCount":102},[],{"trials":5151,"activeCount":102},[],{"trials":5153,"activeCount":102},[],{"trials":5155,"activeCount":102},[5156],{"nctId":5157,"briefTitle":5158,"status":337,"phases":5159,"primaryCompletion":5160,"completion":5161,"start":5162,"enrollment":5163,"conditions":5164,"interventions":5166},"NCT00477776","Maxolon to Improve Breastmilk Supply in Diabetic Women: a Randomised Controlled Trial",[92],"2008-09","2009-03","2006-04",160,[5165],"Breastfeeding",[5146],{"trials":5168,"activeCount":102},[],{"trials":5170,"activeCount":102},[5171],{"nctId":5172,"briefTitle":5173,"status":337,"phases":5174,"primaryCompletion":5175,"completion":5176,"start":5177,"enrollment":5163,"conditions":5178,"interventions":5179},"NCT00264719","Metoclopramide to Aid Establishment of Breastfeeding:a Randomised Controlled Trial",[94],"2008-05","2009-05","2006-01",[5165],[5146],{"intervention":5181,"totalTrials":133,"cells":5182},"Utilization of the conventional circuit",{"EARLY_PHASE1":5183,"PHASE1":5185,"PHASE2":5187,"PHASE3":5189,"PHASE4":5191,"NA":5193},{"trials":5184,"activeCount":102},[],{"trials":5186,"activeCount":102},[],{"trials":5188,"activeCount":102},[],{"trials":5190,"activeCount":102},[],{"trials":5192,"activeCount":102},[],{"trials":5194,"activeCount":102},[5195],{"nctId":5196,"briefTitle":5197,"status":337,"phases":5198,"primaryCompletion":5199,"completion":5200,"start":4578,"enrollment":2304,"conditions":5201,"interventions":5204},"NCT03657225","Mini Versus Conventional Cardiopulmonary Bypass In CABG in Asian Patients",[94],"2013-07","2014-07",[5202,5203],"Acute Kidney Injury","Neurological Injury",[5181],{"intervention":5206,"totalTrials":133,"cells":5207},"Hydrocortisone-Lidocaine",{"EARLY_PHASE1":5208,"PHASE1":5210,"PHASE2":5212,"PHASE3":5214,"PHASE4":5216,"NA":5218},{"trials":5209,"activeCount":102},[],{"trials":5211,"activeCount":102},[],{"trials":5213,"activeCount":102},[],{"trials":5215,"activeCount":102},[],{"trials":5217,"activeCount":102},[],{"trials":5219,"activeCount":102},[5220],{"nctId":5221,"briefTitle":5222,"status":141,"phases":5223,"primaryCompletion":5224,"completion":5224,"start":5225,"enrollment":378,"conditions":5226,"interventions":5228},"NCT05165875","Splint Versus Steroid Randomized Trial",[94],"2024-02","2022-06",[5227],"De Quervain Syndrome",[5206],{"intervention":5230,"totalTrials":133,"cells":5231},"continuous vancomycin",{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5236,"PHASE3":5238,"PHASE4":5240,"NA":5242},{"trials":5233,"activeCount":102},[],{"trials":5235,"activeCount":102},[],{"trials":5237,"activeCount":102},[],{"trials":5239,"activeCount":102},[],{"trials":5241,"activeCount":102},[],{"trials":5243,"activeCount":102},[5244],{"nctId":5245,"briefTitle":5246,"status":141,"phases":5247,"primaryCompletion":340,"completion":340,"start":5248,"enrollment":5249,"conditions":5250,"interventions":5252},"NCT01720940","Reducing Nephrotoxicity of Vancomycin: A Prospective Study of Continuous Versus Intermittent Infusion of Vancomycin",[94],"2012-10",220,[5251],"Infections Requiring Prolonged Duration (>10 Days) of Vancomycin",[5230,5253],"intermittent vancomycin",{"intervention":5253,"totalTrials":133,"cells":5255},{"EARLY_PHASE1":5256,"PHASE1":5258,"PHASE2":5260,"PHASE3":5262,"PHASE4":5264,"NA":5266},{"trials":5257,"activeCount":102},[],{"trials":5259,"activeCount":102},[],{"trials":5261,"activeCount":102},[],{"trials":5263,"activeCount":102},[],{"trials":5265,"activeCount":102},[],{"trials":5267,"activeCount":102},[5268],{"nctId":5245,"briefTitle":5246,"status":141,"phases":5269,"primaryCompletion":340,"completion":340,"start":5248,"enrollment":5249,"conditions":5270,"interventions":5271},[94],[5251],[5230,5253],{"intervention":5273,"totalTrials":133,"cells":5274},"esomeprazole",{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5279,"PHASE3":5281,"PHASE4":5283,"NA":5285},{"trials":5276,"activeCount":102},[],{"trials":5278,"activeCount":102},[],{"trials":5280,"activeCount":102},[],{"trials":5282,"activeCount":102},[],{"trials":5284,"activeCount":102},[],{"trials":5286,"activeCount":102},[5287],{"nctId":5288,"briefTitle":5289,"status":337,"phases":5290,"primaryCompletion":5291,"completion":5291,"start":2851,"enrollment":2255,"conditions":5292,"interventions":5294},"NCT00786695","Study Using Esomeprazole as a Diagnostic Test for GERD in Patients With NCCP",[94],"2009-12",[5293],"Gastroesophageal Reflux Disease",[5273],{"intervention":5296,"totalTrials":133,"cells":5297},"Do not receive IV albumin",{"EARLY_PHASE1":5298,"PHASE1":5300,"PHASE2":5302,"PHASE3":5304,"PHASE4":5306,"NA":5308},{"trials":5299,"activeCount":102},[],{"trials":5301,"activeCount":102},[],{"trials":5303,"activeCount":102},[],{"trials":5305,"activeCount":102},[],{"trials":5307,"activeCount":102},[],{"trials":5309,"activeCount":102},[5310],{"nctId":5311,"briefTitle":5312,"status":141,"phases":5313,"primaryCompletion":339,"completion":2323,"start":2601,"enrollment":378,"conditions":5314,"interventions":5317},"NCT02811406","The Role of Intravenous Albumin Replacement During Abdominal Paracentesis in Patients With Malignancy Related Ascites",[94],[5315,5316],"Ascites","Hypotension",[5296],{"intervention":5319,"totalTrials":133,"cells":5320},"EMLA",{"EARLY_PHASE1":5321,"PHASE1":5323,"PHASE2":5325,"PHASE3":5327,"PHASE4":5329,"NA":5331},{"trials":5322,"activeCount":102},[],{"trials":5324,"activeCount":102},[],{"trials":5326,"activeCount":102},[],{"trials":5328,"activeCount":102},[],{"trials":5330,"activeCount":102},[],{"trials":5332,"activeCount":102},[5333],{"nctId":5334,"briefTitle":5335,"status":141,"phases":5336,"primaryCompletion":5337,"completion":5337,"start":5338,"enrollment":5339,"conditions":5340,"interventions":5342},"NCT01330615","Efficacy Trial of Eutectic Lidocaine\u002FPrilocaine Cream 5% (EMLA) for Analgesia Prior to Cryotherapy of Verrucae Plantaris",[94],"2010-12","2010-02",64,[5341],"Plantar Warts",[5319],{"intervention":5344,"totalTrials":133,"cells":5345},"Exemestane",{"EARLY_PHASE1":5346,"PHASE1":5348,"PHASE2":5350,"PHASE3":5352,"PHASE4":5354,"NA":5356},{"trials":5347,"activeCount":102},[],{"trials":5349,"activeCount":102},[],{"trials":5351,"activeCount":102},[],{"trials":5353,"activeCount":102},[],{"trials":5355,"activeCount":102},[],{"trials":5357,"activeCount":102},[5358],{"nctId":5359,"briefTitle":5360,"status":141,"phases":5361,"primaryCompletion":339,"completion":807,"start":5362,"enrollment":2229,"conditions":5363,"interventions":5365},"NCT01655004","Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD",[94],"2012-08",[5364],"Breast Carcinoma",[5344],{"intervention":5367,"totalTrials":133,"cells":5368},"COVID-19 vaccine",{"EARLY_PHASE1":5369,"PHASE1":5371,"PHASE2":5373,"PHASE3":5375,"PHASE4":5377,"NA":5379},{"trials":5370,"activeCount":102},[],{"trials":5372,"activeCount":102},[],{"trials":5374,"activeCount":102},[],{"trials":5376,"activeCount":102},[],{"trials":5378,"activeCount":102},[],{"trials":5380,"activeCount":102},[5381],{"nctId":5382,"briefTitle":5383,"status":141,"phases":5384,"primaryCompletion":5385,"completion":5386,"start":5387,"enrollment":575,"conditions":5388,"interventions":5391},"NCT04802278","Gestational Immunity for Transfer",[],"2021-06-01","2021-12-01","2020-05-01",[5389,5165,5390],"Covid19","Vaccine Exposure Via Breast Milk",[5367]]